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LOOKING BEYOND JUDICIAL DEFERENCE
TO AGENCY DISCRETION:
A FUNDAMENTAL RIGHT OF ACCESS TO RU 486?
INTRODUCTION
At New York City's John F. Kennedy International Airport
on July 1, 1992, Leona Benten walked off an international
flight into a public maelstrom. Six and one-half weeks preg-
nant, unemployed and single, she carried a small amount of an
unapproved French abortifacient known as RU 486.1 Ms.
Benten hoped to use the drug, as prescribed by her physician,2
to terminate her pregnancy in the privacy of her home. She
sought to use an existing exception to statutory bans on unap-
proved drugs that allows an individual to import a small
amount of an unapproved drug for her personal use while
under the supervision of a physician. Nevertheless, upon noti-
fying an agent of the United States Customs Service that she
possessed the drug, Ms. Benten was detained by Customs and
Food and Drug Administration ("FDA") agents and the drug
was seized. Although she sued the Commissioners of the FDA
and the Bureau of Customs and, although she prevailed in the
District Court for the Eastern District of New York, the United
I The name "RU 486" is the manufacturer's internal designation for
mifepristone. Different spellings include "RU-486" and "RU486;" this Note employs
the spelling used by the inventors. See Michael Klitsch, Antiprogestins and the
Abortion Controversy: A Progress Report, 23 FAM. PLAN. PERSP. 275 (1991). See
generally Rebecca J. Cook, Antiprogestin Drugs: Medical and Legal Issues, 42 MER-
CER L. REV. 971 (1991); Sarah Ricks, The New French Abortion Pill: The Moral
Property of Women, 1 YALE J.L. & FEMINISM 75 (1989). See also Martha Minow,
Breaking the Law: Lawyers and Clients in Struggles for Social Change, 52 U. PiT.
L. REV. 723 (1991) (considering ethical issues confronting lawyers interested in
challenging existing law using RU 486 hypothetical).
2 Dr. Louise Tyrer, Ms. Benten's physician, is a prominent obstetri-
cian/gynecologist licensed to practice medicine in California and Nevada. She was
well-qualified to examine Ms. Benten and to recommend, prescribe and supervise
Ms. Benten's use of RU 486. Under the FDA's regulations, unapproved drugs may
be imported for personal use with the advice and supervision of a physician. See
infra notes 97-105 and accompanying text.
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States Court of Appeals for the Second Circuit granted a stay
of the district court decision, and the United States Supreme
Court refused to vacate the stay.3 Ultimately, Ms. Benten was
unable to use RU 486 and underwent a surgical abortion.
RU 486 had already been recognized by members of Con-
gress,4 state and city governments,5 physicians,6 pro-choice
See infra notes 115-33 and accompanying text.
In February 1991, Representative Robert Dornan (R.-Cal.) introduced legisla-
tion to forbid "federal financial assistance in any form" to research medical uses of
RU 486. During the same month, Representative Ron Wyden of Oregon submitted
a bill that would have overturned the FDA import ban on the drug. THE PINK
SHEET, Feb. 11, 1991 (FDC Reports). In 1992, similar bills were introduced in both
the House, by Representative Ron Wyden, and the Senate, by Senator Alan
Cranston of California. The House bill had sixty co-sponsors. Sylvia Bennett,
102nd Congress' Attention to Cancer Remains Significant, 84 J. NATL CANCER
INST. 841-42 (1992). Legislation to permit research on RU 486 by the National
Institutes of Health was also submitted to the House in 1993 and co-sponsored by
Representatives Wyden, Henry Waxman (D.-Cal.), Pat Schroeder (D.-Colo.) and
Peter DeFazio (D.-Ore.). NIH Reauthorization Hearing Tentatively Planned for Jan.
21; Wyden Introduces RU 486 Research Bill, THE BLUE SHEET, Jan. 6, 1993, at 2-3
(FDC Reports). Despite some legislators' interest in RU 486, Congress has not
acted to alter the FDA's import ban or to facilitate research on the drug.
Representative Wyden, Chairman of the Subcommittee on Regulation, Business
Opportunities and Energy of the House of Representative's Committee on Small
Business, has held three public hearings on RU 486. Through these hearings, he
has attempted to encourage the manufacturer to submit evidence of RU 486's
safety and efficacy to the FDA for its approval. See RU 486: The Import Ban and
its Effect on Medical Research: Hearings Before the Subcomm. on Regulation, Busi-
ness Opportunities, and Energy of House of Rep. Comm. on Small Business, 101st
Cong., 2d Sess. 53 (1990) [hereinafter Hearing 1]; The Safety and Effectiveness of
the Abortifacient RU 486 in Foreign Markets: Opportunities and Obstacles to U.S.
Commercialization: Hearing Before the Subcomm. on Regulation, Business Opportu-
nities, and Energy of the House of Rep. Comm. on Small Business, 102d Cong., 1st
Sess. 65-66 (1991) [hereinafter Hearing 21; The Effect of the Federal Ban of RU
486 on Medical Research, New Drug Development, and Pharmaceutical Manufactur-
ers, Hearings Before the Subcomm. on Regulation, Business Opportunities, and
Energy of the House of Rep. Comm. on Small Business, 102d Cong., 1st Sess.
(1992) [hereinafter Hearing 3].
' The former Mayor of New York City, David Dinkins, organized a petition-
writing campaign to encourage Roussel-Uclaf, a French subsidiary of a large Ger-
man multinational, Hoechst Corporation, to submit RU 486 to the FDA for approv-
al and garnered signatures from many of the mayors of the largest cities. Klitch,
supra note 1, at 280. The presence of these signatories is significant because wom-
en in large urban centers probably would be the first to use RU 486. Since the
present medical protocol calls for two visits to a physician for the administration
of the drug, urban women have greater access than rural women to a network of
clinics that would provide follow-up care.
In addition to efforts by city officials, the state legislatures of California, Ore-
gon and New Hampshire have passed resolutions urging Reussel to initiate the
approval process. Id.
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and pro-life activists' and Administration officials8 as a drug
with the potential to alter fundamentally the highly conten-
tious and politicized debate on the topic of abortion. Although
pro-choice activist groups had attempted to encourage the
manufacturer, Roussel-Uclaf, to begin the standard, new-drug
application process in the United States,9 the French company
hesitated under threats of boycotts by pro-life groups." In a
Efforts such as these by city and state officials do not have any direct influ-
ence on whether a drug is approved by the FDA. Rather they are intended to
demonstrate to the manufacturer and the FDA that there is public interest in the
drug and a desire among many for its approval and availability.
" Eighty-five percent of obstetricians and gynecologists polled at a medical
conference said they would prescribe the drug. See Around the U.S., DALLAS
MORNING NEWS, May 18, 1993, at 8A.
, "Pro-choice" and "pro-life" are labels adopted by the activists involved in the
abortion debate. As the President of the National Right to Life Committee, the
well-known pro-life group, Richard Glasow, stated, "We [the National Right to Life
Committee] have been following the results of tests of RU 486 closely since 1985."
Hearing 2, supra note 4. Other pro-life advocates, like the American Life League,
have also vowed their opposition to "the birth control pill, RU-486, Norplant and
Depo-Provera, each of which also act to abort tiny babies after their lives begin at
fertilization." Judie Brown, Opposition Clear, CFH. TRaB., Apr. 3, 1993, at N24
(President of League's letter to the editor)
8 Dr. Jocelyn Elders, the Surgeon-General, has "vowed ...to make the abor-
tion pill RU 486 'available in this country.'" See Elizabeth Neuffer, View on Teen-
Age Pregnancy May Spark Fiery Hearings on Surgeon-General Pick, BOSTON
GLOBE, July 15, 1993, at 1; see also Robin Toner, Settling In: Easing Abortion
Policy; Clinton Orders Reversal of Abortion Restrictions Left by Reagan and Bush,
N.Y. TIMES, Jan. 23, 1993, at 1 ("[President Clinton] also called for a review of
the ban on the importation of the French abortion drug, RU-486, for personal
use."). President Clinton's action did not lift the import ban on RU 486. Rather,
he signed an executive order directing that the Secretary of the Department of
Health and Human Services, Donna Shalala, "promptly instruct the FDA to deter-
mine whether there is sufficient evidence to warrant exclusion of RU 486 from the
list of drugs that qualify" for the personal use exemption to the ban on importa-
tion. Safeguards for Fetal Tissue Transplantation Research Featured in NIH Reau-
thorization Bill, THE BLUE SHEET, Jan. 27, 1993, at 3-4 (FDC Reports) (numerous
news stories); see Ron Wyden, Let the Pill Into the U.S., N.Y. TIMES, Apr. 10,
1991, at A25 (former President Bush concerned about funding of World Health
Organization research efforts involving RU 486).
' If a drug manufacturer wants to distribute an unapproved drug in the Unit-
ed States, it must submit a New Drug Application ("NDA7) to the FDA. 21 C.F.R.
§ 314 (1993); see U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, REQUIRE-
MENTS OF LAWS AND REGULATIONS ENFORCED BY THE U.S. FOOD AND DRUG AD-
MINISTRATION 39-41 (1989). The manufacturer's NDA must include safety and effi-
cacy data from adequate and well-controlled scientific studies.
" See generally LAWRENCE LADER, RU 486-THE PILL THAT COULD END THE
ABORTION WARS AND WHY AMERICAN WOMEN DO NOT HAVE IT 41 (1991). Roussel
is the foremost producer of steroids in the world and engages in business in over
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preemptive strike, however, the FDA acted against the drug. It
issued an order to its import enforcement and Customs agents
requiring them automatically to seize RU 486 under all cir-
cumstances.
This action and the FDA's subsequent refusals to lift the
import ban appear to have violated both the agency's own
regulations and federal law governing agency rulemaking.
When an agency, such as the FDA, does not follow proper
rulemaking procedures, it acts outside the scope of its statuto-
ry authority. In so doing, the agency improperly extends the
scope of its discretion. The possibility that an administrative
agency could independently broaden its discretion threatens
the existing system of administrative rulemaking, which pro-
vides for public involvement. Since agency officials are not
elected, substantive regulations issued by administrative agen-
cies must be reviewed by courts. In the absence of meaningful
90 countries. Roussel was partially nationalized in 1982 when the French govern-
ment bought 36.25% of its stock. Hoechst retains 54.5% of Roussel stock, and the
remaining shares are publicly held. Id. This division of company assets affected
the conflict over RU 486's development and subsequent debates about its avail-
ability in European countries and the United States. The French foreign ministry
was supportive of its development and distribution. Id. at 49. Hoechst, on the
other hand, was reticent to encourage production for several reasons. First, its
President, Wolfgang Hilger, is Roman Catholic and strongly pro-life. Second,
Hoechst's corporate forerunner, I.G. Farben, had manufactured the poison gas used
in World War II death camps, and Hoechst was sensitive to any negative publicity
engendered by historical association. Finally, Hoechst was concerned about jeopar-
dizing $6 billion in annual profits in the United States market if RU 486 became
available and anti-abortion groups organized a successful boycott. Id. at 49-50.
Roussel decided to manufacture RU 486 for French distribution and on September
23, 1988, the French government announced its availability. Id. at 50. One month
later, on October 26, after protests led by Catholic priests and doctors, Roussel
announced that it would not produce RU 486. Id. The French health ministry
swiftly responded two days later in a strongly worded statement, asserting RU 486
was the "moral property of women" and ordering Roussel to continue distribution.
Id. at 51; see also Hearing 2, supra note 4, at 12 (testimony of Dilys Cossey,
Chairwoman, British Family Planning Association, England). Since Roussel was
partially nationalized and since the French government has the power to strip a
company of its license and award it to a competitor, the French government was
suitably situated to exert such influence. LADER, supra, at 51-52. There is some
evidence to suggest that Roussel never intended to stop production, but rather
announced that it would to secure a greater base of political support. No matter
what its motivation, Roussel's action generated tremendous publicity for RU 486,
contributed to a higher level of consumer education about the drug and encour-
aged physicians who might have remained silent to declare their support for its
availability. Id. at 50-51.
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judicial review, those affected are left without a legal remedy.
In addition to raising issues of administrative rulemaldng,
examining Ms. Benten's situation also provides an opportunity
to consider women's role in determining health care policy and
the importance of participatory decisionmaking processes for
traditionally absent classes of persons. In addition, her case
warrants special attention for it is the first in a line of cases
that will challenge the existing contours of constitutional doc-
trine defining the rights to birth control and abortion.
This Note explores the FDA's use of import bans as a form
of administrative rulemaking and asserts that by imposing the
ban, the FDA violated procedural requirements for issuing
regulations and acted arbitrarily and capriciously. This Note
also asserts that RU 486 as a new reproductive health technol-
ogy may challenge the Supreme Court to reconsider its classifi-
cation of a woman's constitutional right to choose birth control
as greater than her right to choose abortion. Ultimately, the
Court may ratify, once again, a woman's fundamental right to
choose abortion at the onset of pregnancy, unimpeded by state
restrictions.
Part I describes the drug, RU 486, at which the import
ban was directed and surveys the scientific data on its safety
and efficacy. The Note then recounts the history of drug regu-
lation in the United States and considers the nature of admin-
istrative rulemaldng generally, and the appropriate standard
of judicial review of agency regulations. Part I also considers
the enforcement efforts of the FDA with particular emphasis
on a regulation entitled the "personal use exception," which
permits individuals to import unapproved drugs. Part II of this
Note then analyzes the FDA's import ban on RU 486 and Ms.
Benten's arguments in her suit against the FDA. Finally, the
Note considers in Part III the involvement of women in form-
ing women's health care policy and the import ban's negative
effect on participation. The Note concludes with an analysis of
how RU 486 will impact significantly existing Supreme Court






RU 486, a steroid hormone, appears to be a safe and effec-
tive way to terminate pregnancy." To date, over 120,000 Eu-
ropean women have taken the drug. 2 It is approved for use
as an abortifacient and widely available to women in France,
Great Britain and Sweden. 3
Its efficacy has been proven in a number of large-scale
clinical trials conducted by the developer, and in independent
analyses by researchers reviewing the drug's use in France,
England and Scotland. 4 The efficacy rate ranges from ninety-
six percent 5 to ninety-nine percent, depending on the drug
protocol followed. 6 RU 486 may be used up to the ninth week
of pregnancy without diminishing its effectiveness. 7
The drug continues to be the focus of intense interest
among medical researchers around the world. Chinese scien-
tists are testing RU 486 as an abortifacient. 8 Studies in Can-
ada and the Netherlands are evaluating the drug's potential as
" See Mifepristone, Micromedex, 1993, available in LEXIS, Genmed Library,
Medex File (a comprehensive medical analysis of RU 486 intended for health pro-
fessionals).
12 Telephone Interview with Graydon Forrer, Counsel to the Subcommittee on
Regulation, Business Opportunities, and Energy of the House of Representatives
Committee on Small Business (Nov. 19, 1992).
13 Philip J. Hilts, Abortion Pill's Sale Unlikely Soon Despite Change of Admin-
istration, N.Y. TIMES, Nov. 13, 1992, at 38.
1 Klitsch, supra note 1, at 275 n.6; see also David A. Grimes, Mifepristone (RU
486) for Early Abortion, in 2 OBSTETRICS/GYNECOLOGY REP. 91 (1990); Louise
Silvestre et al., Voluntary Interruption of Pregnancy with Mifepristone (RU 486)
and a Prostaglandin Analogue: A Large Scale French Experience, 322 NEW ENG. J.
MED. 645 (1990); Andr6 Ulmann et al., RU 486, 262 Sci. AM. 42 (1990).
Klitsch, supra note 1, at 275.
16 When given with oral prostaglandin, see infra notes 38-39 and accompanying
text, the administration of RU 486 will terminate pregnancies in ninety-nine per-
cent of its users. See Elyse Tanouye, Abortion Procedure Is Found to be 99% Effec-
tive, WALL ST. J., May 27, 1993, at B6 (reviewing research published in the New
England Journal of Medicine).
17 Klitsch, supra note 1, at 276 n.12.
"l Fox Butterfield, In New Hampshire, A Move to Test Abortion Pill, N.Y.
TIMES, May 5, 1991, at 28. A pro-choice group has begun testing a Chinese ver-
sion of RU 486 on animals in the United States in an effort to encourage Roussel-
Uclaf to seek FDA approval for RU 486. See Philip J. Hilts, Abortion Rights
Group Uses Chinese Pill to Goad French, N.Y. TIMES, Feb. 18, 1993, at B9.
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an anti-cancer agent, particularly for breast 9 and brain can-
cers.2" In Scotland, RU 486 is being studied as a morning-
after pill, contraceptive and an abortifacient.2 Other promis-
ing applications include its use as a cure for disfiguring hor-
monal disorders such as Cushing's Syndrome.22 RU 486 also
has been used effectively to encourage labor induction,23 treat
ectopic pregnancies' and diminish the effects of endometrio-
sis.25
In the United States, clinical trials testing RU 486 as an
abortifacient were to have begun during the summer of 1993 in
Oregon. The trials were to have been directed by the Popula-
tion Council, a non-profit research group that was negotiating
a licensing agreement with Roussel-Uclaf." As of January 1,
" Telephone Interview with Graydon Forrer, supra note 12; see Susan Jenks,
RU 486 Enters Limited Clinical Trials, 84 J. NAT'L CANCER INST. 563 (1992).
2 See S.W.J. Lamberts et al., Mifepristone (RU 486) Treatment of Meningiomas,
abstraction reprinted in International Abstracts, 268 JAMA 3428 (1992) (RU 486
limited tumor growth in majority of patients).
" The "morning-after pill" has typically been a high-dose birth control pill
administered after unprotected intercourse to prevent pregnancy. See Klitsch, supra
note 1, at 277; Gina Kolata, New Use is Found for Abortion Pill, N.Y. TIMES, Oct.
8, 1992, § 6 (Magazine), at Al ("Both treatments [RU 486 and birth control pills]
prevented pregnancy in women who had had unprotected sexual intercourse in the
preceding 72 hours . . . but RU 486 caused far less nausea and vomiting."); see
also Anna Glasier et al., Mifepristone (RU 486) Compared With High-Dose Estrogen
and Progestogen for Emergency Postcoital Contraception, 327 NEW ENG. J. MED.
1041-44 (1991); Jan Hoffman, The Morning-After Pill: A Well-Kept Secret, N.Y.
TIMES, Jan. 10, 1993, § 6 (Magazine), at 12, 14 ("The side effects of RU 486, when
used as a morning-after pill, are considerably less unpleasant than those of birth-
control pills used for the same purpose.").
See Mifepristone, supra note 11.
R. Frydman et al., Labor Induction in Women at Term with Mifepristone
(RU 486): A Double-blind, Randomized, Placedo-controlled Study, 80 OBSTET-
RICS/GYNECOLOGY REP. 972 (1992), as abstracted by LEXIS, Genmed library,
Medline file ("[We have found mifepristone to be a safe, efficient, and suitable
induction agent for initiation of labor in women at term.").
2 Daniel J. Garry et al., Are There Really Alternatives to the Use of Fetal
Tissue From Elective Abortions in Transplantation Research, 327 NEW ENGL. J.
MED. 1592 nn.8 & 14 (1992).
25 See Klitsch, supra note 1, at 277; see also Philip J. Hilts, Study Set on
Abortion Pill's Use in Breast Cancer, N.Y. TIMES, Dec. 5, 1991, at 22; Sharyn
Thylan, RU 486 May Also Help Alleviate Endometriosis, N.Y. TIMES, Oct. 30, 1992,
at A30 (letter to the editor from President of Endometriosis Alliance of Greater
New York reviewing study by University of California scientists that explored the
use of RU 486 for treatment of endometriosis).
2' See Warren E. Leary, Maker of Abortion Pill Reaches Licensing Pact with
U.S. Group, N.Y. TIMES, Apr. 21, 1993, at A18; Associated Press, Controversial
Abortion Pill to Get First U.S. Clinical Trials in Oregon, L.A. TIMES, May 1, 1993,
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1994, it was unclear when clinical trials would actually be-
gin." The researcher who developed RU 486 has reached a
preliminary agreement with the manufacturer to distribute the
drug in the U.S. as soon as the drug has received FDA approv-
al.28 Once there are small-scale trials and a reliable produc-
tion source, FDA approval of the drug as an abortifacient ap-
pears likely. 9 Already, an expert panel appointed by the Na-
tional Academy of Sciences' Institute of Medicine has hailed
the class of drugs to which RU 486 belongs, the antiprogestins,
as showing significant promise in a variety of medical applica-
tions. 0 Indeed, the FDA has approved a clinical trial of RU
486 for the treatment of breast cancer.3'
Part of RU 486's appeal is its potential to alter a woman's
at A8. Roussel-Uclaf's negotiations concerning a licensing agreement with the Pop-
ulation Council is a political saga with a soap-opera-like plot twists and turns.
Since the late 1980s, Roussel-Uclaf and its parent company, Hoescht, had been
repeatedly contacted by the drug's American proponents and foes. Since the elec-
tion of a pro-choice President, additional pressure encouraging Roussel-Uclaf either
to market the drug in the U.S. or to select a licensing partner has been exerted
by Administration, agency and congressional officials. For a chronology of these
developments, see News Capsules, THE BLUE SHEET, Feb. 10, 1993 (FDC Reports)
(HHS Secretary directs FDA to review agency import ban on RU 486 through
published notice in Federal Register); RU 486 Review by FDA Could Be Completed
Six Months Following an NDA Submission, Agency Tells Wyden, THE BLUE SHEET,
Dec. 30, 1992 (FDC Reports); Three Firms Express Interest in Marketing RU 486
in U.S.; Wyden Asks Roussel-Uclaf to Seek U.S. Partner, THE BLUE SHEET, Dec. 9,
1992, at 14 (FDC Reports); Associated Press, French Abortion Pill Will Be Tested
in U.S., N.Y. TIMES, Mar. 18, 1993, at A18 (Russel-Uclaf identifying research
partners in response to official request from President Clinton's administration;
clinical trials to begin in two months); Philip J. Hilts, Door May Be Open for
Abortion Pill to be Sold in U.S., N.Y. TIMES, Feb. 25, 1993, at Al (President of
Roussel-Uclaf and FDA Commissioner meet to discuss RU 486 approval and mar-
keting in U.S.); Leary, supra, at A18.
27 Tamar Lewin, Plans For Abortion Pill Stalled in U.S., N.Y. TIMES, Oct. 13,
1993, at A17; Elyse Tanouye, Legal Import of Abortion Pill Appears Near, WALL
ST. J., Jan. 24, 1994, at B1.
Reuters, Deal Seen on Abortion Pill, N.Y. TIMEs, Nov. 15, 1993, at A12.
29 Large Phase III Trials of RU 486 in U.S. Should Not Be Required for FDA
Approval, Institute of Medicine Report Concludes, THE BLUE SHEET, Sept. 15, 1993
(FDC Reports); RU 486 Timetable Will Depend on Establishment of Manufacturing
Capacity by U.S. Marketer, THE BLUE SHEET 8, May 26, 1993 (FDC Reports).
"2 Warren E. Leary, Broader Uses Seen for Abortion Pill, N.Y. TIMES, Sept. 9,
1993, at A17.
"1 Associated Press, Abortion Pill Approved for Breast Cancer Test, N.Y. TIMES,
Nov. 19, 1993, at A20. California researchers are also evaluating RU 486 as a
treatment for prostate and brain cancer. See Patricia Anstett, Brain Tumor Re-
search Called Hopeful, DETROIT FREE PRESS, Apr. 5, 1993, at 1G.
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experience of terminating a pregnancy. RU 486 also allows a
woman to be a substantially more active participant in the
abortion. She ingests the pills and experiences a heavy period
rather than being partially or fully anesthetized and having
medical personnel perform an invasive surgical procedure on
her." At least one, small-scale study has examined women's
reactions and determined that ninety-four percent of the users
found the procedure satisfactory because the process seemed
more natural or empowering than a surgical abortion. 3
RU 486 also provides women with the opportunity to have
a non-surgical abortion in the privacy of their homes, thus
avoiding pro-life activists at abortion clinics. 4 As tactics used
by some pro-life activists have become more violent, the efforts
of local law enforcement have been unable to ensure access to
*1 Contrast the non-surgical abortion method to a description of the surgical
technique:
Before dilating the uterus, the size and location of the uterus is deter-
mined by clinical examination. The vagina, vulva and cervix are
scrubbed. ... Dilation of the cervix is next accomplished using Hegar's
or Pratt dilators, cylindrical instruments employed to probe and dilate
the cervix. .. .Once the cervix is dilated adequately, the uterus is evac-
uated .... [A] suction curette aspirator will be introduced into the uter-
us after cervical dilation. When the tube is inserted into the uterus, it is
drawn back and forth from the fundus or upper portion of the uterus to
the cervix or lower portion and rotated in all directions .... If parts of
the placenta or fetal parts remain in the body, they may be removed
with a sharp curet. Complete removal of the fetus is always mandato-
ry ... to avoid continued bleeding and infection.
Benten v. Kessler, 799 F. Supp. 281, 284 n.3 (E.D.N.Y. 1992) (citing ROSCOE N.
GRAY, ATrORNEY'S TEXTBOOK OF MEDICINE § 311.84(1) (3d ed. 1991)), stay granted,
(2d Cir.), application to vacate denied, 112 S. Ct. 2929 (1992).
' Klitsch, supra note 1, at 277; see also JANICE G. RAYMOND ET AL., RU 486
MISCONCEPTIONS, MYTHS AND MORALS (1991) (arguing that women should not
accept medical abortion techniques without evaluating risks of ingesting relatively
new chemical technologies when there is a relatively simple and safe surgical
alternative).
"' A number of pro-life groups, including "Operation Rescue," have blocked or
sought to limit patient access to health care clinics that provide abortion services.
See Associated Press, Court Allows Challenge to Clinic Blockades, N.Y. TIMES, Oct.
31, 1993, at A22. Operation Rescue's leader, Randall Terry, a colorful character,
was found guilty of criminal contempt for violating an injunction when he con-
fronted then-Governor Bill Clinton with a fetus during the 1992 Democratic Na-
tional Convention. Randall Terry Receives Jail Sentence, REPROD. FREEDOM NEWS,
July 2, 1993, at 7 (Ctr. for Reproductive Law and Policy, New York, N.Y.). For a
discussion of the propriety of issuing injunctions against pro-life blockades of abor-
tion clinics, see Carolyn Grose, Note, "Put Your Body on the Line:" Civil Disobedi-
ence and Injunctions, 59 BROOK. L. REV. 1497 (1994).
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clinics for patients and staff.5 And while pro-life demonstra-
tors physically block access to clinics, other factors, including
restrictive state abortion laws,36 a shortage of physicians pro-
viding abortion services and remoteness of clinics, also may
make it difficult for women to obtain surgical abortions.37
A woman may use the medical abortion technique as soon
as she realizes she is pregnant rather than waiting until she is
seven weeks pregnant, the earliest time at which she could
obtain a surgical abortion. She ingests 600 milligrams of RU
486 in pill form. Since RU 486 inhibits progesterone, the hor-
mone necessary for the development of a uterine lining to sus-
tain a fertilized egg, the uterus will begin to shed its lining."
Thirty-six to forty-eight hours later, the woman receives an
oral form of a prostaglandin, a synthetic hormone, which
speeds up the flushing of the uterine lining.39 The medical
" Recently, in National Org. for Women v. Scheidler, 114 S. Ct. 798 (1994),
the Supreme Court held that clinic operators and prosecutors could use racketeer-
ing laws (RICO) to punish pro-life demonstrators who conspire to close or damage
health care clinics that provide abortion services. Violators charged with conspiring
to violate RICO may be liable for treble damages.
Among federal law enforcement officials there is a growing consensus that
federal legislation is necessary in order to protect clinics adequately, particularly
in light of the murder of a Florida physician, Dr. David Gunn. Attorney General
Janet Reno has stated that the "passage of this legislation is a priority." See Mi-
chael Isikoff, Administration Will Attempt to Make Obstructing Abortion Clinics a
Felony, WASH. POST, Mar. 24, 1993, at A13; see also Associated Press, Reno Vows
Inquiries into Abortion Violence, N.Y. TIMES, Oct. 31, 1993, at A22.
"s As locating a clinic at which to receive a surgical abortion has become more
difficult, women have sought "at-home" alternatives including a procedure called
"menstrual extraction." See Women Turn to Self-Help Groups for Abortions, Despite
the Risks, N.Y. TIMES, Sept. 9, 1992, at C13.
" Eighty-three percent of American counties have no abortion provider, a figure
that will surely increase as most medical schools no longer train medical students
in surgical abortion techniques. Since states may pass restrictions on abortion ser-
vices ranging from parental consent for minors to waiting periods and counseling
directives, these restrictions in combination with a decreasing number of providers
will make it even more difficult for women to seek surgical abortions at clinics.
For a comprehensive account of legal restrictions on abortion and practical consid-
erations that continue to reduce women's access to surgical abortion services, see
Janet Benshoof, Planned Parenthood v. Casey: The Impact of the New Undue Bur-
den Standard on Reproductive Health Care, 269 JAMA 2249 (1993). See also Sara
Rimer, Abortion Clinics Seek Doctors But Find Few, N.Y. TIMES, Mar. 31, 1993, at
A14; Joannie M. Schrof, Reproduction Showdown: Advocates Predict the Abortion
Pill Will Revolutionize Women's Health, U.S. NEWS & WORLD REP., Mar. 22, 1993,
at 32.
38 Grimes, supra note 14, at 91.
3' See Klitsch, supra note 1, at 276; Tanouye, supra note 16, at B1.
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abortion technique enables women to avoid risks associated
with surgical abortion including infections, serious physical
injury to the uterus or the cervix and complications arising
from anaesthesia."
The side effects associated with RU 486 include bleeding,
nausea, and uterine cramping. One study characterizes the
average blood loss as "clinically unimportant," "like a heavy
period" which does "not disrupt[] [women's] usual activities."'
In addition, studies suggest that only one percent of users
experience excessive menstrual bleeding requiring either vacu-
um aspiration or curettage.4 2 The most serious side effects are
associated not with RU 486 but with a class of drugs called
prostaglandins. One of these, Cytotec, would have been admin-
istered with RU 486 to Ms. Benten. Cytotec is FDA-approved
and readily available in the United States. 3 There have been
three cases of prostaglandin-related cardiovascular complica-
tions and one fatality resulting from the medical abortion tech-
nique.4 These complications, however, arose in association
with the use of another prostaglandin, not Cytotec.4 ' Never-
theless, if the patient is over thirty-five-years-old or smokes,
the RU 486 protocol may not be appropriate.46
B. The Food and Drug Administration
Had RU 486 been developed in the nineteenth century
there would have been no effort to regulate it. Federal regula-
tion of the pharmaceutical industry began in 1906 when Con-
gress passed the Pure Food and Drug Act4 The Act required
that drugs sold in interstate commerce must not be mislabelled
'6 See Schrof, supra note 37, at 32.
41 Grimes, supra note 14, at 94.
Klitsch, supra note 1, at 275-76.
Cytotec, a hormone-like fatty acid also known as misoprostal, has been ap-
proved by the FDA for the prevention of ulcers. Trade & Gov't Memos, THE PINK
SHEET, May 31, 1993 (FDC Reports). Once the FDA approves a drug for one use,
a physician may prescribe it for other purposes. Jane E. Henney, The Changing
Approval Process, 47 FOOD DRUG COSM. L.J. 505, 507 (1992) ("[Plhysicians, of
course, may prescribe approved drugs for uses they find appropriate.").
"' Trade & Gov't Memos, supra note 43.
45 Id.
46 Id.
'1 HENRY G. GRABowSKI & JOHN M. VERNON, THE REGULATION OF PHARIMA-
CEUTICALS: BALANCING THE BENEFITS AND RISKS 1 (1983).
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or adulterated. It did not, however, require that the safety or
efficacy of drugs be substantiated before the drugs were sold to
consumers.48 A public health crisis involving numerous poi-
soning deaths from the drug sulfanilamide dramatized this
dangerous flaw in the legislation.49 In response to the tragedy,
Congress repealed the 1906 Act and passed the Federal Food,
Drug, and Cosmetic Act of 1938 ("FDCA"), a more comprehen-
sive regulatory scheme. 0 Under the new legislation a manu-
facturer was required to submit a new drug application
( NDA")5 before its drug could be introduced into interstate
commerce. The NDA directed a drug company to specify the
purpose of the new drug and demonstrate its safety.53 The
manufacturer, however, did not have to establish the efficacy
of a new drug and NDAs were automatically approved within
sixty days of filing, unless regulators undertook specific action
against a drug.54
Uncomfortable with an automatic approval process that
did not require a manufacturer to prove the effectiveness of a
new drug, Congress acted to amend the FDCA to include an
efficacy requirement. In 1962 it passed the Kefauver-Harris
amendments to the FDCA.55 The amendments required com-
48 Id. at 1-2.
, More than 100 children died upon ingesting a new liquid form of a popular
sulfa drug, sulfanilamide. The manufacturer, Massengill Company, combined the
sulfanilamide with a poisonous chemical solvent, diethylene glycol, without per-
forming toxicity studies to ensure the chemical's safety. Id. at 2.
" Federal Food, Drug, and Cosmetic Act ("FDCA"), ch. 675, 52 Stat. 1040 (cod-
ified as amended at 21 U.S.C. §§ 301-31 (1988)). The FDA is a division of the
Public Health Service of the Department of Health and Human Services. The
Secretary of Health and Human Services, who is a member of the Cabinet, directs
the Department's programs and goals. A Commissioner, appointed by the President
with consent of the Senate, oversees the day to day activities of the FDA. UNITED
STATES GOVERNMENT MANUAL 301-14 (1993).
51 21 U.S.C. § 355 (1988 & Supp. IV 1992).
52 U.S. CONST., art. I, § 8, cl. 3. The "commerce clause" is the source of the
federal government's power to regulate interstate commercial activity.
63 GRABOWSKI & VERNON, szpra note 47, at 2.
54 Id.
" Id. at 3. The amendments were spurred by a widely reported tragedy involv-
ing the drug thalidomide. When thousands of pregnant women in Europe took
Thalidomide, a sleeping aid with anti-nausea effects, their children were born with
serious birth defects. The disaster spurred Americans to consider the risks of new
drugs. Fortunately, thalidomide had been introduced in the United States only for
investigational use and had not been approved for widespread distribution. Max
Sherman & Steven Strauss, Thalidomide: A Twenty-Five Year Perspective, 41
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panies to submit evidence from adequate and well-controlled
clinical trials that a new drug was safe and effective.56 With
this change, pharmaceutical companies were required to take
affirmative steps to gain FDA approval before a drug could
enter the stream of interstate commerce." Through the
Kefauver-Harris amendments, the federal government was no
longer simply an "evaluator of evidence and research findings,"
but had become an "active participant" in the development of
safe, effective drugs.58
C. Rulemaking by Administrative Agencies
1. A Period of Public Notice and Comment
Administrative agencies, such as the FDA, are governmen-
tal hybrids with both regulatory and enforcement powers.
When Congress grants rulemaking authority to administrative
agencies through enabling statutes, Congress delegates its
constitutional power to legislate.59 Specific enabling statutes
define the role of each agency, its ability to write and enforce
regulations and the scope of its discretion. Congress relies on
an agency's expertise and enhanced ability to generate detailed
policies and appropriately precise regulations."
FOOD, DRUG COSM. L.J. 458 (1986); see also Mindy J. Lees, Note, I Want a New
Drug: RU-486 and the Right to Choose, 63 S. CAL. L. REV. 1113, 1134 n.175
(1990).
" GRABOWSKI, supra note 47, at 3.
57 Id. at 3-4.
58 Id. at 4.
59 U.S. CONST., art. I, § 8.
60 See generally Sidney A. Shapiro & Robert L. Glicksman, Congress, The Su-
preme Court, and the Quiet Revolution in Administrative Law, 1988 DUKE L.J.
819. Most enabling statutes, until recently, have been broadly written delegations
of authority to regulate. When enabling legislation is general in scope, proponents
may more easily build consensus around its passage. Id. Congress may increase its
own efficiency by delegating its regulatory authority. Since agencies have greater
expertise in their specific topic area and larger staffs to develop and implement
policy, Congress finds it useful to delegate the task of drafting detailed regulations
to agencies. Of course, in doing so, Congress also delegates legislative power and
control, which implicates the balance of power between the different branches of
government. See infra note 61.
The independence of agencies may also be curtailed by Congress. For exam-
ple, in the area of environmental law Congress has sought to limit the Environ-
mental Protection Agency's power in order to regain control of environmental is-
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In an effort to standardize proper procedures for agency
action, Congress passed the Administrative Procedure Act
("APA" or "Act"). The Act outlined the rulemaking authority of
administrative agencies and described what formal procedures
an agency must follow to promulgate binding regulations.6'
The statutory scheme mandates that when issuing a binding
regulation that either exceeds the express scope of congres-
sional legislation or may impact substantive rights, an agency
first must provide for a period of notice by publication in the
Federal Register and then solicit public comment.62 Such reg-
sues. Id. Congress could enact similar legislation to control more tightly FDA
activities such as the agency's use of import alerts like RU 486. See infra notes
192-93 and accompanying text.
61 5 U.S.C. §§ 551, 553 (1988). The APA was passed in 1946 to control and
standardize administrative procedures. KENNETH F. WARREN, ADMINISTRATIVE LAW
IN THE POLITICAL SYSTEM 267 (1988). The growth of administrative agencies and
the influence of agency officials has significant constitutional implications for the
separation of powers. Id. at 265-66. For example, as the size of administrative
agencies increases and as agencies, instead of Congress, set policy and draft regu-
lations, the executive branch assumes some of the rulemaking authority tradition-
ally exercised by Congress. The language of 5 U.S.C. § 551 defines "agency," "rule"
and "rulemaking" as follows:
(1) 'agency' means each authority of the Government of the United
States, whether or not it is within or subject to review by another agen-
cy, but does not include-(A) the Congress; (B) the courts of the United
States; (C) the governments of the territories or possessions of the United
States; (D) the government of the District of Columbia....
(4) "rule" means the whole or a part of an agency statement of general
or particular applicability and future effect designed to implement, inter-
pret, or prescribe law or policy or describing the organization, procedure,
or practice requirements of an agency....
(5) "rule making" means agency process for formulating, amending, or
repealing a rule.
Section 553 sets forth the rulemaking scheme incorporating a requirement of pub-
lic notice:
(b) General notice of proposed rule making shall be published in the
Federal Register, unless persons subject thereto are named and either
personally served or otherwise have actual notice thereof in accordance
with law. The notice shall include-(1) a statement of the time, place,
and nature of public rule making proceedings; (2) reference to the legal
authority under which the rule is proposed; and (3) either the terms or
substance of the proposed rule or a description of the subjects and issues
involved.
62 5 U.S.C. § 553 (1982):
(b) . . . Except when notice or hearing is required by statute, this sub-
section does not apply-(A) to interpretative rules, general statements of
policy, or rules of agency organization, procedure, or practice; or (B) when
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ulations are regarded as "legislative" or "substantive" rules.
Thus, the APA both ensures that individuals have notice of
and an opportunity to comment on proposed rules that may
impact their substantive rights and permits citizens to petition
for the implementation, change or revocation of rules. 3
No notice and comment procedure is required, however, if
an agency issues an "interpretative" rule, clarifying its own
policies or regulations. Presumably an interpretative rule im-
pacts only the agency's internal operations or is a statement of
policy which will not affect the substantive rights of those
regulated. In contrast, a "legislative" rule is more similar to a
new law, the effects of which will extend to persons outside of
the agency." When an agency's regulatory action is best char-
acterized as a "legislative" rule, the APA notice and comment
procedure is necessary. If an agency does not follow the notice
and comment requirements of the APA when issuing regula-
tions, a court may invalidate the regulation on procedural
grounds.65
2. Scope and Standard of Judicial Review
In addition to setting forth procedural guidelines for agen-
cies generating regulations, the APA codified Congress's pre-
sumption that final agency action would be reviewable by the
the agency for good cause finds (and incorporates the finding and a brief
statement of reasons therefor in the rules issued) that notice and public
procedure thereon are impracticable, unnecessary, or contrary to the pub-
lic interest.
(c) After notice required by this section, the agency shall give interested
persons an opportunity to participate in the rule making through submis-
sion of written data, views, or arguments with or without opportunity for
oral presentation....
(d) The required publication or service of a substantive rule shall be
made not less than 30 days before its effective date, except-() a sub-
stantive rule which grants or recognizes an exemption or relieves a re-
striction; (2) interpretative rules and statements of policy; or (3) as other-
wise provided by the agency for good cause found and published with the
rule.
(e) Each agency shall give an interested person the right to petition for
the issuance, amendment, or repeal of a rule.
6Id.
64Id.
See infra notes 155-171 and accompanying text (discussing scope of judicial
review of agency action).
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courts.66 Generally, agency determinations are accorded con-
siderable deference by courts.67 When a court must evaluate a
factual determination by an agency, agency administrators
must provide a sufficiently detailed evidentiary record for the
court to evaluate whether agency action was supported by
substantial evidence. 68 At the same time, a court may not re-
quire agencies to follow procedures not contemplated by the
APA when the agency generates regulations.69 If the agency
record is insufficient, the reviewing court should not attempt to
rationalize some basis for agency action7" and may find the
" See 5 U.S.C. §§ 551-59, 701-06 (1982). Section 706 provides:
To the extent necessary to decision and when presented, the reviewing
court shall decide all relevant questions of law, interpret constitutional
and statutory provisions, and determine the meaning or applicability of
the terms of an agency action. The reviewing court shall-(1) compel
agency action unlawfully withheld or unreasonably delayed; and (2) hold
unlawful and set aside agency action, findings, and conclusions found to
be-(A) arbitrary, capricious, an abuse of discretion, or otherwise not in
accordance with law; (B) contrary to constitutional right, power, privilege,
or immunity; (C) in excess of statutory jurisdiction, authority, or limita-
tions, or short of statutory right; (D) without observance of procedure
required by law; (E) unsupported by substantial evidence in a case sub-
ject to sections 556 and 557 of this title or otherwise reviewed on the
record of an agency hearing provided by statute....
Id. § 706. The requirement of final agency action ensures that agencies have suffi-
cient autonomy to make decisions, independently develop a factual record and
determine how to allocate resources. Public Citizen v. Commissioner, Food and
Drug Admin., 740 F.2d 21, 29 (D.C. Cir. 1984) (FDA rulemaking on issue of label-
ing of aspirin was ongoing and, thus, not suitable for review); see also Cutler v.
Hayes, 818 F.2d 879, 896 (D.C. Cir. 1987) ("An agency has broad discretion to set
its agenda and to first apply its limited resources to the regulatory tasks it deems
most pressing.").
67 Chevron, U.S.A., Inc. v. Natural Resources Defense Council, 467 U.S. 837,
844 (1984) (considerable deference is accorded administrative interpretations of
enabling statute); Fidelity Fed. Say. and Loan Ass'n v. de la Cuesta, 458 U.S. 141,
169-70 (1982) (administrator's actions should be subject to judicial review,only if
arbitrary or if actions exceed statutory authority).
68 5 U.S.C. § 706(2)(E) (1982); see FTC v. Indiana Fed'n of Dentists, 476 U.S.
454, 477 (1986) (finding that the court must accept the Commission's findings of
fact if supported by such relevant evidence as a reasonable mind might accept as
adequate); see also National Nutritional Foods Ass'n v. Weinberger, 512 F.2d 688,
700-01 (2d Cir.), cert denied, 423 U.S. 827 (1979) (substantial evidence test applied
to proceedings which are the subject of hearing provisions of 5 U.S.C. § 556 or
557).
"' Vermont Yankee Nuclear Power Corp. v. Natural Resources Defense Council,
Inc., 435 U.S. 519, 545-48 (1978) (finding that a court must be careful not to in-
vade the domain which Congress has set aside for an administrative agency).
70 Bowen v. American Hosp. Ass'n, 476 U.S. 610, 627 (1986).
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agency action arbitrary and capricious.71
Although most agency decisions are subject to judicial
review using the arbitrary and capricious standard, the APA
created two limited exceptions. Judicial review of an agency's
determination is not appropriate when an enabling statute
expressly precludes it72 or if the administrative decision at
issue is "committed to agency discretion by law."73 According-
ly, in Citizens to Preserve Overton Park v. Volpe,74 the Court
determined that the scope of agency immunity as set forth in
these exceptions is "very narrow"75 and limited to statutes
"drawn in such broad terms that in a given case there is no
law to apply."76 In this instance, the Volpe Court considered
whether the court could review the Secretary of Trans-
portation's decision to approve the use of federal funds for
highway construction where a highway would traverse and
bisect parkland. The Court first concluded that the Secretary
should be accorded some discretion.77 The Volpe Court then
determined that it nevertheless could review the Secretary's
decision to determine whether the "decision was based on a
consideration of the relevant factors."' Through the review
process, the court could ensure that the Secretary had ade-
quately considered existing federal laws protecting public
parkland.79 Thus, as long as there is a judicially cognizable
standard embodied in the statute that circumscribes agency
action, agency decisionmaking remains subject to review by
courts."0
"' Citizens to Preserve Overton Park v. Volpe, 401 U.S. 402, 416 (1971); see
infra notes 74-79 and accompanying text.
5 U.S.C. § 701(a)(1) (1982).
7' Id. § 701(a)(2).
14 401 U.S. 402 (1971).
7" Id. at 410.
" Id. at 410 (quoting S. REP. No. 752, 79th Cong., 1st Sess. 26 (1945)).
71 Id. at 415-16.
78 Id. at 416.
73 Id. at 412-14.
" Heckler v. Chaney, 470 U.S. 821, 834-35 (1985) (holding no judicial review of
FDA's refusal to take enforcement action under the FDCA where prisoners sought
to force the FDA to challenge the state's use of certain drugs for lethal injections).
Heckler's implications for judicial review of agency discretion has been comprehen-
sively reviewed by commentators. See Elizabeth L. Crittenden, Heckler v. Chaney:
The Presumption of Unreviewability in Administrative Nonenforcement Cases, 89 W.
VA. L. REV. 363 (1987) (presumption against judicial review in cases of agency
nonfeasance is major shift in administrative law and deprives citizens of opportu-
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Guaranteeing the availability of judicial review is an es-
sential part of ensuring procedural due process for persons
affected by agency rulemaking.1 Whether drafting enabling
legislation like the FDCA for specific agencies or sweeping
legislation, such as the APA, Congress has assumed that judi-
cial review will temper agency discretion." In the absence of
judicial review, administrative agencies would exist almost as
an autonomous "fourth branch" of government, independently
carrying out the policies of the President through extensive
drafting of substantive legislation in the form of regulations,
rather than as an enforcement arm of the Executive branch
regulated by Congress. 3 The constitutional doctrine of sepa-
ration of powers guarantees that each branch of government
will be able to carry out its constitutionally defined role and
provide a check on the other branches of government. If one
could not bring a legal challenge to the actions of administra-
tive agencies or the scope of an agency's discretion, the neces-
sary balance of power between the three branches of govern-
ment would be disrupted.
Additionally, our democratic system of government as-
sumes that the public will influence federal policy primarily
through electing representatives to the Congress, although
citizens also vote for the chief executive. Yet, in the twentieth
nity to challenge agency discretion); Shapiro & Glicksman, supra note 60, at 854-
58; Cass R. Sunstein, Reviewing Agency Inaction after Heckler v. Chaney, 52 U.
CHI. L. REV. 653 (1985) (judicial review of agency inaction should be available if
enforcement decision violates statutory constraints); Sharon Werner, The Impact of
Heckler v. Chaney on Judicial Review of Agency Decisions, 86 COLUM. L. REV.
1247 (1986) (agency decisionmaking is reviewable under Heckler v. Chaney if judi-
cially manageable standards exist).
" Cynthia R. Farina, Statutory Interpretation and the Balance of Power in the
Administrative State, 89 COLUM. L. REV. 452, 482 (1989) (an active judicial branch
ensures a functioning system of checks and balances in a tripartite government).
At least one commentator has remarked that judicial review is an integral part of
the APA's regulatory scheme. KENNETH DAVIS, ADMINISTRATIVE LAW OF THE
EIGHTIES §§ 7:8-:12 (Supp. 1989).
"Z Abbott Labs. v. Gardner, 387 U.S. 136, 142 (1967) ("There is always an
appropriate remedy in equity in cases where an administrative officer has exceed-
ed his authority and there is no adequate remedy of law ... " (quoting H.R. REP.
No. 2755, 74th Cong., 2d Sess. 8 (1936)).
" Peter L. Strauss, The Place of Agencies in Government: Separation of Powers
and the Fourth Branch, 84 COLUMI. L. REV. 573 (1984) (examining the relationship
of congressional authority to executive authority in the control of administrative
agencies).
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century, the role of administrative agencies and their size and
complexity have greatly increased as agencies have become
more involved in quasi-legislative activities of regulation and
policy development. Since administrative agencies have become
an essential feature of the federal government and because
agency officials are not elected, a citizen's right to vote is no
longer a sufficiently direct means of influencing policy. Thus,
judicial review ensures the accountability of agency officials,
who are political appointees and, unlike congressional repre-
sentatives, do not face re-election.' Judicial review also guar-
antees that agencies remain participatory in character and
that citizens may still play a role in policy definition.
3. FDA Regulatory Authority
The procedural requirements of the FDA's enabling stat-
ute, the FDCA, parallel the APA's standards for rulemaking
and judicial review.85 The Commissioner of the FDA may pro-
mulgate necessary and appropriate regulations to fulfill FDA's
health and safety mandate." Proposed agency regulations are
first subject to notice and comment procedures like those of the
APA, including publication in the Federal Register and a peri-
od of public comment.87 The FDCA also provides for judicial
review of agency rulemaking using the standards adopted by
the APA.88 Since the FDA's enabling statute has parallel pro-
cedural requirements to the APA, and since Congress passed
the APA specifically to standardize administrative proce-
dures, 9 the APA's procedural requirements and standard of
judicial review provide the appropriate analytical framework to
"' Thomas McGarity, Some Thoughts on "Deossifying" the Rulemaking Process,
1992 DUKE L.J. 1385 (regulatory vehicles for policymaking should be participatory).
" The FDA's regulatory scheme predates the APA but has been revised to con-
form with the APA. The regulations articulating the FDA's procedures appear in
the Code of Federal Regulations. 21 C.F.R. §§ 10.25, 10.30 & 10.40 (1992).
EG 21 C.F.R. § 10.40 (1992).
67 Id.
" Specific provisions outlined in 21 U.S.C. § 371(f)()-(6) (1982) indicate that a
court may review agency decisions to determine if the actions of administrators
are based on substantial evidence. These provisions supplemented existing chan-
nels of judicial review and predated the APA by eight years. Abbott Labs. v.
Gardner, 387 U.S. 136, 142 (1967).




evaluate FDA's enforcement policies and rulemaking.
D. The FDA's Enforcement Efforts
To introduce a new drug into the United States market, a
manufacturer must undertake the FDA's drug approval proce-
dure. The FDCA prohibits any pharmaceutical company from
bypassing the regulatory process."° A company or individual
may not import a new, "unapproved" drug,91 defined as any
drug that is "forbidden or restricted in sale in the country in
which it was produced" or "is adulterated [or] misbranded."92
The United States Customs Service enforces the import regula-
tions of the FDA. All shipments of goods subject to FDA con-
trol-drugs, food, medical devices and cosmetics-may be in-
spected as they are cleared through customs.93 To ensure that
dangerous substances do not enter the United States, two
special FDA procedures have been implemented. First, the
FDA may issue an import alert concerning a specific drug. The
import alert is an internal memorandum issued by FDA ad-
ministrators through the Office of Import Operations to field
agents in district offices. The alert advises field personnel and
Customs agents of "new or unusual problems affecting im-
ports."94 It provides identifying information about a product,
"' Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 331 (1982).
21 U.S.C. § 355 (1982).
Id. § 381(a)(2)-(3).
93 See DEPARTMENT OF HEALTH AND HUMAN Svcs., FOOD AND DRUG ADMINIS-
TRATION, FDA'S IMPORT COVERAGE APPROACHES (1982) (HHS Pub. No. (FDA) 82-
1085) [hereinafter, FDA's IMPORT COVERAGE APPROACHES]; DEPARTMENT OF HEALTH
AND HUMAN Svcs., FOOD AND DRUG ADMINISTRATION, FDA'S IMPORT ENFORCEMENT
OPERATIONS (1982) (HHS Pub. No. (FDA) 81-1086) [hereinafter, FDA'S IMPORT EN-
FORCEMENT OPERATIONS]; see also John R. Fleder, The Role of the Department of
Justice in Enforcement Matters Relating to the Food and Drug Administration, 46
FOOD DRUG COSM. L.J. 781-92 (1991) (Director of Office of Consumer Litigation,
Civil Division, U.S. Dep't of Justice's explanation of efforts to ensure compliance
through civil and criminal enforcement actions); Paul M. Hyman, Legal Overview
of FDA Authority Over Imports and Exports, 42 FOOD DRUG COSM. L.J. 203-12
(1987) (outlining FDA's authority in import cases); Marie A. Urban, The FDA's
Policy on Seizures, Injunctions, Civil Fines, and Recalls, 47 FOOD DRUG COSM. L.J.
411-19 (1992) (Director of Compliance Management and Operations, FDA'a Office
of Enforcement/Regulatory Affairs' description of enforcement policies).
94 FDA'S IMPORT COVERAGE APPROACHES, supra note 93, at 3. The FDA has
issued import alerts to notify Customs agents to intercept a wide variety of drugs
of dubious value. The character of drugs named in import alerts ranges from the
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the reasons for the alert and instructions for responding to an
entry application.
The second procedural mechanism is to issue an automatic
detention order. The FDA will automatically retain or deny
entry to products under such detention orders without examin-
ing products individually.95 Detention orders are based on a
history of violations by a shipper or based on a product's coun-
try of origin. 6 Import alerts may be used in the announce-
ment of automatic detention orders. The purpose of both these
administrative tools is to ensure an efficient regulatory re-
sponse by the agency.
1. The Personal Use Exception
While drugs that have not gone through the FDA approval
process may not be sold in the United States, the FDA has a
longstanding policy of allowing individuals to import for their
unusual and medically useless to the extremely dangerous. A recent survey of
import alerts includes the following drugs: abortafacients, European diet drugs,
evening primrose oil, ginseng, herbal medicines, anabolic steroids and adrenal
cortex extract. 1531 Food Drug Cosm. L. Rep. (CCH) 7244-45 (1992).
The difference between the average drug alert and the drug alert for
abortafacients is notable. In almost all cases, the FDA has included in its alert a
specific reason suggesting why the import of the drugs must be scrutinized more
carefully. Id. at 7244. For abortafacients, however, there is no proffered scientific
rationale, only a reference to the import alert number. Id. ("All shipments of un-
approved abortifacient drugs should be automatically detained.").
'5 See generally DEPARTMENT OF HEALTH AND HUMAN SERVICES, FDA IMPORT
OPERATIONS BRANCH: FISCAL YEAR 1991-WORLD WIDE IMPORT DETENTION SUMMA-
RY (1991) (comprehensive summary of all import alerts issued worldwide organized
by region and substance).
" Id.; see also Telephone Interview with John Brown, Consumer Safety Officer,
Import Operations Branch, Food and Drug Administration (Sept. 18, 1992) (notes
on file with the Brooklyn Law Review). Examples of drugs that are subject to -
automatic detention include L-Tryptophan, Dr. Johnson's and Dr. Sister Comple-
ment for Weight Loss, Interferon, "714x" Cancer/AIDS serum, anabolic steroids,
Laetrile, Oil of Evening Primrose, homeopathic drugs, Woodward's Gripe Water,
"Tatex" Tattoo Remover, Eagle Brand Medicated Oil, Mexican folk remedies, "P2P"
(an ingredient used in the manufacture of amphetamines), Dimethyl Sulfoxide,
Trichosanthin (Compound Q) and anti-aging cream. FOOD AND DRUG ADMINISTRA-
TION, IMPORT ALERT INDEX (Aug. 31, 1992) (Pub No. #92-11). Each of these exam-
ples is either a remedy with little, if any, recognized medical benefit or is a drug
that poses a known and substantial health risk to the user. In contrast, research
on RU 486 has generated substantial evidence of the drug's safety and efficacy.




personal use small quantities of unapproved drugs that do not
appear to pose a significant threat to a user's health or safety.
This policy was first outlined in a 1954 directive from the
FDA's Division of Field Operations to all district offices.97 In
1977, the FDA Regulatory Procedures Manual provided for
importation of unapproved drugs through mail shipments as
long as an importer's physician requested the release of the
detained drugs, and the drugs were shipped in personal bag-
gage.9
8
The policies set forth in the Regulatory Procedures Manual
were updated in 1988 through an import alert entitled "Pilot
Guidance for Release of Mail Importations."' This alert al-
lowed unapproved drugs that had been purchased for personal
use, in non-commercial quantities, to avoid detention altogeth-
er.00 The alert set forth only a few situations when the ship-
97 Hearing 1, supra note 4, at 175-77 (Letter from Acting Commissioner of the
FDA to Assistant Secretary for Health (Nov. 19, 1990)).
" Id. at 176.
99 Id. at 162-63 (July 20, 1988 import alert issued by the Director of Regional
Operations).
"® Id. at 163. The updated 1988 mail import policy has been viewed as an
attempt to be particularly responsive to individuals suffering from terminal illness-
es such as AIDS. AIDS activists have criticized the FDA's regulation of new drugs,
arguing that the existing drug approval process keeps life-prolonging treatments
from patients, and they have sought to speed drug trials to provide quicker access.
While patients with HIV have been permitted to bring in unapproved drugs of
questionable safety and efficacy under the 1988 mail import policy, women seeking
to import RU 486 have been thwarted by the import ban. See infra notes 97-114
and accompanying text (discussing FDA's mail import policy). See generally Marga-
ret Salmon Rivas, The California AIDS Initiative and the Food and Drug Adminis-
tration: Working at Odds With Each Other?, 46 FOOD DRUG COSM. L.J. 107 (1991)
(criticizing the federal government's lack of a national AIDS policy); Gene P.
Schultz & Charles A. Parmenter, Medical Necessity, AIDS, and the Law, 9 ST.
LOuIS U. PUB. L. REV. 379 (1990) (discussing state's obligation to provide medical
services to patients with AIDS); Jon S. Batterman, Note, Brother Can You Spare a
Drug: Should the Experimental Drug Distribution Standards be Modified in Re-
sponse to the Needs of Persons With AIDS?, 19 HOFsTRA L. REV. 191 (1990) (criti-
cizing lack of FDA approved drugs for treatment of AIDS); John Patrick Dilhnan,
Note, Prescription Drug Approval and Terminal Diseases: Desperate Times Require
Desperate Measures, 44 VAND. L. REV. 925 (1991) (criticizing FDA's conservative
stance with respect to new AIDS drugs), Bret L. Lansdale, Note, A Procedural
Due Process Attack on FDA Regulations: Getting New Drugs to People With AIDS,
18 HASTINGS CONST. L.Q. 417 (1991) (arguing that the FDA deprives people with
AIDS of their interests in life and liberty by precluding them from obtaining life
extending drugs); Beth E. Myers, Note, The Food and Drug Administration's Ex-
perimental Drug Approval System: Is it Good for Your Health?, 28 HOuS. L. REV.
309 (1991) (recognizing that FDA "red tape" prevents critically ill patients from
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ment should be detained: for fraudulent promotion or misrep-
resentation or if the unapproved drug presents an "unreason-
able health risk due to toxicity or possible contamination," or if
the size of the shipment suggests it will be distributed com-
mercially.'' While the alert indicated that the FDA con-
ceived of this policy as discretionary, the alert is an authorita-
tive policy statement by the FDA that allows individuals to
import unapproved drugs for personal use under the supervi-
sion of a physician on a case-by-case basis." 2
The FDA formally incorporated the provisions of the 1988
mail import alert into the Regulatory Procedures Manual in
December 1989 without changing or expanding the mail import
policy.0 3 The Manual designates two situations when unap-
choosing "risky" drugs).
101 Hearing 1, supra note 4, at 163.
102 Id.
103 Id. at 167 (citing FOOD AND DRUG ADMINISTRATION REGULATORY PROCEDURES
MANUAL, PUB. No. 90-02, pt. 9-71 (Dec. 11, 1989)). The FDA's Division of Field
Investigations issued the following information to its enforcement officers to update
the chapter of the Manual on Coverage of Importations Contained in Personal
Baggage and Pilot Guidance for Release of Mail Importations:
BACKGROUND: There has always been a market in the United States
for some foreign made products that are not available domestically....
Individuals seek medical treatments that are not available in this coun-
try.... With increasing international travel and world trade, we can
anticipate that more people will purchase products abroad that may not
be approved, may be health frauds, or may be otherwise not legal for
sale in the United States .... ITreatments may be promoted to individ-
uals who believe that treatments available abroad will be effective in the
treatment of serious conditions such as AIDS or cancer. Because some
countries do not regulate or restrict the commercial exportation of unap-
proved products, people who mall order from these businesses may not be
afforded the protection of either foreign or U.S. laws. In view of the
potential scale of such commercial operations, FDA has focused its en-
forcement resources more on products that are shipped commercially....
GENERAL GUIDANCE: Even though all products that appear to be in
violation of statutes administered by FDA are subject to refusal, FDA
personnel may use their discretion to examine the background, risk, and
purpose of the products before making a final decision....
DRUGS, BIOLOGICS, AND DEVICES: When personal shipments of
drugs and devices that appear violative are brought to FDA's attention
by Customs, FDA personnel will have to use their discretion to decide on
a case by case basis whether to sample or detain. Generally, drugs . . .
subject to Import Alerts are not amenable to this guidance .... In decid-
ing whether to exercise discretion to allow personal shipments of
drug(sic) ... , FDA personnel should consider a more permissive policy
in the following situations:
e when the intended use is appropriately identified, such use is
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proved drugs may be imported under the personal use excep-
tion. In the first scenario, an unapproved drug may be allowed
to enter the United States when the intended use is identified
and the product is not known to represent a significant health
risk regardless of whether or not the importer suffers from a
serious illness. 10 4 The second category provides that importa-
tion is permissible if the importer has a serious condition,
there is no reasonable alternative treatment and the drug does
not pose an unreasonable health risk. In addition, the importer
of the drug must provide the name and address of the super-
vising physician and must not attempt to commercialize the
drug.0 5
2. The Automatic Detention of RU 486
With the incorporation of the 'Policy Guidance" provisions
into the Regulatory Procedures Manual, RU 486 seemed to be
a proper candidate for importation under either scenario of the
personal use exception. 1 6 Following the first scenario, one
could import RU 486 as long as one specified the intended use
since the drug does not present a serious health risk.0 7 The
second set of circumstances would permit the importation of
RU 486 if pregnancy constitutes a serious condition. To meet
the latter importation requirements, an individual seeking to
not for treatment of a serious condition, and the product is not
known to represent a significant health risk; or
9 when 1) the intended use is unapproved and for a serious condi-
tion for which effective treatment may not be available domestical-
ly either through commercial or clinical means; 2) there is no
known commercialization or promotion to persons residing in the
U.S. by those involved in the distribution of the product at issue;
3) the product is considered not to represent an unreasonable risk;
and 4)the individual seeking to import the product affirms in writ-
ing that it is for the patient's own use (generally not more than 3
month supply) and provides the name and address of the doctor
licensed in the U.S. responsible for his or her treatment with the
product or provides evidence that the product is for the continu-
ation of a treatment began in a foreign country.
Id. at 168-72.
Id. at 171.
"0 Id. at 171-72.
" See supra notes 11-31 and accompanying text (explaining safety and effec-
tiveness of RU 486).
107 Id.
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import the drug would demonstrate that the existing surgical
abortion technique would not be "effective,""'8 that the im-
porter will not try to promote or market the drug and that the
product does not present an "unreasonable risk.""9 This anal-
ysis of the personal use exception suggests that an individual
would be allowed to import RU 486 under the FDA's policy for
unapproved drugs. Nevertheless on September 26, 1988, FDA
Director of Field Operations, Burton Love, issued an import
alert blocking importation of RU 486 and directing all enforce-
ment personnel to prohibit individuals from importing RU 486
under the 1988 mail import alert.' It remains unclear what
precipitated the imposition of this alert.
Once the mail import policy permitting individuals to
import unapproved drugs was publicized, however, a number of
conservative Senators and Representatives, unaware of the
Love import alert, corresponded with the Commissioner of the
FDA regarding RU 486."' Their major concern was to ensure
... What constitutes an "effective" medical procedure is unclear. For example,
does the availability of a surgical alternative for some women but not others dis-
qualify the "others" from obtaining a medical abortion under the second scenario?
While American women have a constitutional right to choose abortion before a
fetus is viable, a woman's ability to exercise choice may be hampered by many
factors, singly or in combination, that may make a surgical abortion impossible to
obtain. There are constitutionally permitted restrictions on access to surgical abor-
tions which make it difficult if not impossible for some women, particularly low-
income women and women from rural areas, to obtain abortions. These include
twenty-four to forty-eight-hour waiting periods which require at least two visits to
a clinic, raising financial barriers like the cost of lodging, travel expenses, trans-
portation and child care. For minors, the requirement of one or both parents' con-
sent may be an insurmountable obstacle. See Benshoof, supra note 37, at 2249-51
(discussing the Supreme Court's decision in Planned Parenthood v. Casey allowing
states to impose placing constitutionally permissible restrictions on access to surgi-
cal abortions); see also Planned Parenthood v. Casey, 112 S. Ct. 2791 (1992)
(holding state-imposed 24-hour waiting period and parental consent provisions
constitutionally permissible); Stanley K. Henshaw, The Accessibility of Abortion
Services in the United States, 23 FAM. PLAN. PERSP. 246 (1991).
1" See supra notes 11-13 and accompanying text (explaining safety and effec-
tiveness of RU 486).
1 The import alert read as follows:
Type of Alert: Automatic Detention; Product: RU 486 or
"Mifepristone." . . . Charge: "The article is subject to refusal of admission
pursuant to Section 801(a)(3) in that it appears to be a new drug with-
out an effective new drug application (NDA) as required by Section
505(a).... The intended use of such drugs could pose a risk to the
safety of the user.
FOOD AND DRUG ADMINISTRATION IMPORT ALERT NO. 66-47 (Sept. 26, 1988).
.,. Hearing 1, supra note 4, at 180-81 (Letter from Frank E. Young, Commis-
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that RU 486 could not enter the country under the personal
use exception.' One month following this exchange of corre-
spondence, the FDA issued a revised import alert and enlarged
the exception to the personal import policy to require that all
abortifacients, including RU 486, automatically be de-
tained."' Presumably this alert would prohibit someone from
sioner, Food and Drug Administration, to Senator Jesse Helms (undated response
to Senator Helms's letter of February 23, 1989, stating that "We do not believe
that this [personal importation] policy can be appropriately applied to the importa-
tion of RU-486 in that use of the product could present an unreasonable safety
risk.")). Id. at 181; Id. at 183 (Letter from ten Representatives to Commissioner
Young (May 5, 1989)). The Representatives' letter to Commissioner Young asserted
that
[t]he U.S. government should not be involved in abetting abortion. This
includes regulations that would allow the use of abortifacients such as
RU 486 .... We would greatly appreciate a clarification on your policy.
Does your policy directive allow the importation of RU-486 or similar
non-approved abortifacient drugs? If it does, have abortifacients . . . been
imported under your directive? Finally, are there regulations currently
being drafted that would add abortifacients, and specifically RU 486, to
the list of prohibited drugs?
Id.; see also id. at 259-60 (Letter from Otis R. Bowen, Secretary of Health and
Human Services, to Senator Gordon J. Humphrey (April 10, 1986)). Mr. Brown
responded,
Thank you for your recent letters . . . regarding the use of Federal funds
for research on the compound RU 486. Following my meeting with repre-
sentatives of the pro-life movement ... I investigated the use by the
National Institutes of Health ('NIH") of HHS funds to support re-
search . . . The NIH ... has neither supported nor conducted abortifa-
cient research involving RU 486 ... due to the considerable concern
about the potential use of RU 486 as an abortifacient, I have asked the
Director of the National Institutes of Health to continue monitoring close-
ly this biomedical research to assure that no support will be provided to
RU 486 as an abortifacient.
1 The personal use exception was widely discussed in the media and scholarly
journals as a compassionate stance taken by the agency to assist AIDS victims
and other seriously ill patients. See supra note 100 (articles discussing personal
use exception). Health activists had roundly criticized the snaillike pace of the
drug approval process and many FDA critics heralded the reviving of the thirty-
year-old personal use exception. See Hearing 1, supra note 4, at 183 (Letter from
ten Representatives to Commissioner Young ('[T"he December 1988 issue of Ameri-
can Health . . . asserts that you have approved a policy that would allow Ameri-
can citizens to mail order non-approved drugs from overseas . .. [how] . . . could
the FDA possibly allow [RU 4861 to be purchased through mail order?"); see also
id. at 175 (Letter from Acting Commissioner of Food and Drugs to Assistant Sec-
retary for Health (Mar. 10, 1990)) (RU 486 import alert was subject of a Washing-
ton Post editorial).
1.3 Hearing 1, supra note 4, at 185 (citing FOOD AND DRUG ADMINISTRATION
IMPORT ALERT NO. 66-47 (June 6, 1989):
CHARGE: The article is subject to refusal of admission pursuant to Sec-
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importing RU 486 or any other antiprogestin drug even if the
intended use was as something other than an abortifacient.
This revised import alert was updated further on April 17,
1990, by listing the chemical names for RU 486 to enable cus-
toms agents to identify and seize the compound more easi-
ly.114 The history behind the different versions of the import
ban suggest that it was an FDA action borne out of politics not
scientific analysis or health and safety concerns.
II. ANALYSIS: BENTEN V. KESSLER AND THE IMPACT OF
ADMINISTRATiVE RULEMAKING
A. The Legal Proceedings
The courts' decisions in Benten v. Kessler"5 and Ms.
Benten's plight reflect how an agency's rulemaking may signif-
icantly impact the lives and substantive rights of individuals.
tion 801(a)(3) in that it appears to be a new drug without an effective
new drug application (NDA) as required by Section 505(a).
REASON FOR ALERT: Questions have been raised about a new abortifa-
cient product, RU 486 . . . and whether the agency should use its discre-
tion, pursuant to the Pilot Guidance for Release of Mail Importa-
tions . . . or otherwise, to allow its importation for personal use. FDA
has concluded that unapproved products of this kind would be inappropri-
ate for release under the personal importation policy. The intended use
could pose a risk to the safety of the user.
INSTRUCTIONS: Automatically detain all shipments of unapproved abor-
tifacient drugs.
114 FOOD AND DRUG ADMINISTRATION, REGULATORY PROCEDURES MANUAL, No.
66-47 ch. 9-79, Apr. 17, 1990 (revised version).
Type of Alert: Automatic Detention; Product: Abortifacient Drugs; Manu-
facturer: All Unapproved; Reason for Alert: . . . FDA has concluded that
unapproved products of this kind would be inappropriate for release un-
der the personal importation policy. The intended use of such drugs could
pose a risk to the safety of the user....
Instructions: Automatically detain all shipments of unapproved abortifa-
cient drugs.
As of January 1, 1994, FDA had not issued any further alerts concerning RU
486. Instead, in the first days of his administration President Clinton ordered a
review of the reasons for the alert in anticipation of lifting the import ban. See
supra note 8 (discussing Clinton's order for determination of whether import ban
should be lifted).
799 F. Supp. 281 (E.D.N.Y. 1992), stay granted, (2d Cir.), application to
vacate stay denied, 112 S. Ct. 2929 (1992). Upon the Supreme Court's refusal to
vacate the stay granted by the Second Circuit, and after Ms. Benten had obtained
a surgical abortion, the case was dismissed.
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These decisions further highlight the need for participatory
rulemaking. In papers filed in the District Court of the Eastern
District of New York seeking a preliminary injunction granting
her access to the RU 486 that she had sought to import, Ms.
Benten argued that regardless of RU 486's status as an unap-
proved drug, she could import it for her personal use upon the
advice of a physician.116 Her view was in accordance with the
FDA regulatory manual's import regulations, which permit the
importation of small quantities of unapproved drugs under
certain circumstances." 7 Ms. Benten asserted that since
there had been no notice to the public or opportunity to com-
ment on the import ban as required by the APA,' the ban
was invalid.19 But, even if the district court were to find that
no notice and comment were required, Ms. Benten argued, the
import ban was improper because it was arbitrary and capri-
cious. 2 ' By contending that the import ban should be en-
joined, Ms. Benten attempted to assert the rights of individu-
als, as defined under the APA, to take an active role in agency
decisionmaking and, in her case, to gain access to a useful
drug. Her arguments demonstrated how the public had been
excluded from the agency's deliberations on the availability of
an extremely safe and effective drug-a drug that promised a
substantially different and desirable treatment for women
seeking abortions. 2'
The government's response to Ms. Benten's claims relied
on the Supreme Cour's broad protection of agency discretion
articulated in Heckler v. Chaney."2 Arguing that the import
ban was simply an enforcement decision, the government con-
tended that the FDA's action was committed to agency discre-
116 Plaintiffs Memorandum of Law in Support of Plaintiffs Motion for a Tempo-
rary Restraining Order and Preliminary Injunction at 3-4, Benten v. Kessler, 799
F. Supp. 281 (E.D.N.Y. 1992), (No. CV-92-3161) [hereinafter Plaintiffs Memoran-
dum].
.17 See supra notes 97-105 and accompanying text (discussing circumstances
under which importation of unapproved drugs is permissible).
"' See supra notes 59-65 and accompanying text (discussing notice and hearing
provisions required under APA).
119 Plaintiffs Memorandum, supra note 116, at 8-10.
120 Id. at 13-15.
121 Id.
122 470 U.S. 821 (1985); see supra note 80 and accompanying text (discussing
broad protection given to agency discretion).
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tion as a matter of law and, thus, was not subject to judicial
review under the APA."2' Moreover, the government replied
that if the ban was not subject to judicial review, there was no
judicially cognizable standard against which it could be judged
arbitrary and capricious."'
The district court agreed with Ms. Benten's argument that
the APA compelled the FDA to provide the public with notice
and an opportunity to comment on the import ban before tak-
ing action to prohibit the importation of RU 486 for personal
use. The court issued an order granting Ms. Benten access to
the RU 486 that she had attempted to import. 25 In addition,
the court urged the FDA to act quickly to adhere to the APA's
procedural requirements: "The still larger question, whether
RU 486 should be available to women in this country, general-
ly, is not before this Court for decision but should promptly be
addressed by the agency assigned the task of resolving it ac-
cording to the legal procedures mandated by Congress for re-
solving such issues."'26 The court further chided the FDA
stating that, "the defendants would be well advised to put their
administrative house in order" even if the process of soliciting
public comment "will be raucous and emotional," for "in a de-
mocracy the best results over the long run flow from adhering
to the democratic procedures set forth in the country's
laws."'27 In concluding, the district court indicated that while
the court did not need to reach the question whether or not the
import ban was arbitrary and capricious, Ms. Benten had dem-
onstrated a substantial likelihood that the import ban could be
struck down on those grounds as well.'28
Although the district court refused to stay the order grant-
ing Ms. Benten access to RU 486, on appeal to the Second
Circuit, the government was able to secure a stay on the pre-
liminary injunction.'29 The court of appeals heard oral argu-
ment on the defendant's motion to stay the lower court's deci-
" Defendant's Memorandum in Opposition to Plaintiffs Motion for Preliminary
Relief at 15, Benten (No. CV-92-3161).
124 Id. at 15-17.
12 Benten, 799 F. Supp. at 291-92.
126 Id.
'' Id. at 291.
12 Id. at 290.
z" Defendant's Notice of Appeal at 2, Benten (No. CV-92-3161).
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sion on the grounds that Ms. Benten was not entitled to equi-
table relief because she could not demonstrate irreparable
injury. The Second Circuit agreed, and Ms. Benten immedi-
ately appealed to Supreme Court Justice Clarence Thomas to
vacate the stay.' Justice Thomas, in turn, asked the entire
court to consider Ms. Benten's application. In a per curiam
opinion, a majority of seven Justices refused to vacate the stay,
stating only that Ms. Benten had not demonstrated a substan-
tial likelihood of success on the merits."3 ' An eloquent dissent
authored by Justice Stevens however, asserted that "on the
specific facts of the case, the Government's purported interest
[in safety and health] actually supports the applicant's posi-
tion... I am persuaded that the relevant legitimate federal
interest is not sufficient to justify the burdensome consequence
of this seizure.""3 2 Justice Stevens also suggested that the im-
port ban did not appear to be based on scientific proof and,
therefore, was an "undue burden" on Ms. Benten's ability to
exercise her constitutional right to obtain an abortion.'
B. Import Bans as Legislative Rules
The legality of the import ban on RU 486 depends first
upon whether the FDA was required to follow the APA's re-
quirements for notice and comment. If the import ban may be
characterized as a legislative rule under the APA, then the
FDA was required to satisfy notice and comment proce-
dures.3 4 A legislative rule is a "'substantive regulation'
which... 'grants rights, imposes obligations, or produces other
significant effects on private interests,"' whereas an interpre-
... Appellants Memorandum of Law in Support of an Application to Vacate the
Stay Pending Appeal at 1-2, Benten (No. A-40). Each Justice is assigned to one or
more Circuits to hear emergency appeals for relief. Justice Thomas is the designee
for the Second Circuit.
131 112 S. Ct. 2929 (1992) (Stevens, J., dissenting).
"2 Id. at 2931.
1 Id.; see also Planned Parenthood v. Casey, 112 S. Ct. 2791 (1992). For a
discussion regarding whether woman have a fundamental constitutional right to
RU 486, rather than a more limited right that merely may not be unduly bur-
dened, see infra Part III.
" For a discussion of two other FDA "policies"-an alert list and fraud policy,
that critics characterize as substantive regulations which should have been subject
to notice and comment regulations, see Richard S. Morey, Legal and Practical
Concerns with the FDA's Fraud Policy, 47 FOOD DRUG COSM. L.J. 431-435 (1992).
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tative rule reflects an agency's "intended course of action, its
tentative view of the meaning of a particular statutory term, or
internal house-keeping measures organizing agency
activity].""35 Those few courts that have had the opportunity
to consider an FDA import alert correctly characterize it as a
legislative rule within the meaning of the APA. 36
The district court in Bellarno International Limited v.
FDA," 7 for example, had considered whether an import alert
is a legislative rule in the context of a pharmaceutical
company's attempt to reimport drug products manufactured in
the United States. The drugs had been exported for sale and,
upon being shipped back to the United States, had been de-
tained by the FDA pursuant to an import alert. 8' Like the
import alert on RU 486, the import alert considered in
Bellarno was issued by the FDA without prior notice and com-
... Perales v. Sullivan, 948 F.2d 1348, 1354 (2d Cir. 1991) (Department of
Health and Human Services assurance requirement under which patents must
document a disability, was found to be a substantive regulation); see also National
Family Planning and Reprod. Health Ass'n v. Sullivan, 979 F.2d 227 (D.C. Cir.
1992) (abortion counseling regulation forbidding medical personnel from discussing
abortion, promulgated with notice and comment procedure, cannot be substantively
altered by a presidential directive permitting doctors to provide abortion counseling
without following APA notice and comment procedure), supra notes 59-65 and ac-
companying text. The problem of an agency attempting to perform its rulemaking
mandate through its enforcement powers is not unique to the FDA. See generally
ROBERTA S. KAuMEL, REGULATION BY PROSECUTION (1982) (where former SEC
Commissioner Karmel attributed her numerous dissents from the institution of
enforcement proceedings by the SEC to the SEC's apparent policy of performing
its mandate of regulating the securities industry by enforcement actions instead of
through its rulemaking authority); cf. New York City Employees Retirement Sys.
v. SEC, 843 F. Supp. 858 (S.D.N.Y. 1994) (SEC improperly reversed its policy
concerning shareholder proposals in proxy statements through no-action letter
instead of through statutorily mandated notice and comment procedures).
2' The FDA's use of an import ban has rarely been challenged. See Benten v.
Kessler, 799 F. Supp. 281 (E.D.N.Y. 1992) (import alert is a substantive rule and
FDA should have followed notice and comment procedures), stay granted, (2d Cir.),
application to vacate stay denied, 112 S. Ct. 2929 (1992) (refusing to vacate stay
because no substantial likelihood of success on the merits) (Blackmun & Stevens,
JJ., dissenting); Bellarno Int'l v. FDA, 678 F. Supp. 410 (E.D.N.Y. 1988) (holding
FDA import alert providing for detention and re-exportation of over-the-counter
drugs is substantive regulation and invalid due to lack of notice and comment);
United States v. Articles of Drug, Consisting of: 203 paper bags, more or less,
Nos. 84C7677, 85C1879 & 85C6020, 1986 WL 3104 (N.D. Ill. Mar. 18, 1986)
(memorandum opinion) (stating that import alert is substantive rule subject to
notice and comment procedures).
' 678 F. Supp. 410 (E.D.N.Y. 1988).
1 Id. at 411.
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ment procedures." 9 The Bellarno court enumerated four in-
terrelated factors to be considered in determining whether or
not an FDA order is substantive: "the binding effect of the pro-
nouncement[;] ... the degree of discretion accorded the agen-
cy.... in [applying] the pronouncement[;] ... deference to the
agency's... characterization[; and the] language [of] the [pro-
nouncement] itself."" " By issuing a formal directive to all
field offices instructing FDA personnel to seize and detain
abortifacient drugs automatically, the FDA brought its policy
on RU 486 within the ambit of the notice and comment re-
quirements of the APA."
Under Bellarno, the RU 486 import ban is a substantive
rule because: it is binding on both the agency and the import-
er; it does not permit FDA agents to use their discretion in its
application; it is characterized by the agency itself as a rule
and not a general statement of policy; and it uses language
more akin to a mandate. The import ban is absolute, as was
the case in Bellarno, instructing that all field offices "automati-
cally detain all shipments."4 4 Thus, the ban constrains FDA
agents from using their discretion to determine whether to
allow personal importation of abortifacients and RU 486 on a
case-by-case basis.' Moreover, the FDA itself has consistent-
"' Id. at 412.
"0 Id. at 413.
141 See IMPORT BULLETIN NO. 66-B13 (Sept. 26, 1988); IMPORT ALERT No. 66-47
(June 6, 1989); see also National Family Planning and Reprod. Health Assoc. v.
Sullivan, 979 F.2d 227, 229 (D.C. Cir. 1992) ("directives are legislative rules").
142 IMPORT ALERT No. 66-47 (June 6, 1989). The earlier order also explicitly
stated, "this drug [RU 486] will not be allowed entry... ." IMPORT BULLETIN No.
66-B13 (Sept. 26, 1988) (emphasis added); see also Letter from FDA Commissioner
Frank Young to Representative Robert Dornan (June 9, 1989) ("the import
alert . . . instructs our field personnel to prevent the importation of unapproved
abortifacient drugs, such as RU 486."). Therefore, the FDA's internal and external
correspondence suggests that the ban was unequivocal.
143 An interpretative rule does not bind an agency. Public Citizen, Inc. v. Unit-
ed States Nuclear Reg. Comm'n, 940 F.2d 679, 682 (D.C. Cir. 1991) (Nuclear Reg-
ulatory Commission regulation on exemptions from prohibitions on exposure to
radiation was an interpretive rule as the NRC did not intend to be bound by such
regulation). It "genuinely leaves the agency . . . free to exercise discretion." Alaska
v. United States Dep't of Transp., 868 F.2d 441, 445 (D.C. Cir. 1989) (quoting
Community Nutrition Inst. v. Young, 818 F.2d 943, 945-46 (D.C. Cir. 1987)) (man-
datory language, department practice of granting exemptions and publication in
CFR support finding that Department of Transportation orders regarding airline
advertizing are substantive rules.); see also Huberman v. Perales, 884 F.2d 62, 67
(2d Cir. 1989) (stating that substantive rules derive from Health and Human Ser-
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ly characterized the import ban as an absolute rule.'" De-
spite the FDA description of the ban as an interpretative rule
or non-binding policy statement, such representations are not
dispositive 45 As Justice Scalia has noted in another context,
"[t]here is deference and there is deference... [O]f far greater
importance is the language used in the statement itself."'46
The language and tone of the import ban also suggest the ban
is a directive.'47
In addition, the import ban is a legislative rule if it signifi-
cantly impacts the rights of the regulated parties.' The per-
sonal use exception codified in the FDA's Regulatory Proce-
dures Manual granted a woman the right to a case-by-case
vices Secretary's rulemaking authority).
... Hearing 1, supra note 4, at 151 (Statement of Ronald Chesemore, FDA Asso-
ciate Commissioner for Regulatory Affairs) ("[I]f [RU 486] is observed coming into
the country either through the mail or with individual persons, it will be detained
by FDA field personnel and U.S. Customs Service officials.") (emphasis supplied);
see also Kevin W. Saunders, Agency Interpretations and Judicial Review: A Search
for Limitations in the Controlling Effect Given Agency Statutory Constructions, 30
ARiz. L. REV. 769 (1988) (discussing impact of legislative-interpretative distinction).
14. The FDA's description is accorded only limited deference. The Bellarno court,
for instance adopted the plaintiffs assertion that the FDA import alert was a
substantive rule. Bellarno Int'l v. FDA, 678 F. Supp. 410, 415 (1988); see also San
Diego Air Sports Center, Inc. v. Federal Aviation Administration, 887 F.2d 966,
970 (9th Cir. 1989) (holding that FAA letter forbidding parachuting within Air
Terminal Control Area was binding substantive rule and invalid due to FAA's
neglect of required notice and comment procedure).
... Brock v. Cathedral Bluffs Shale Oil Co., 796 F.2d 533, 538 (D.C. Cir. 1986)
(voluntary language in Secretary of Labor's published enforcement policy supports
a finding that it is an interpretive rule).
17 If the ban were simply a policy statement providing guidance for FDA
agents to assist them as they exercise their discretion as representatives of the
FDA, the language would sound more like the example of "guidance" provided by
Bellarno: "We [the FDA] suggest that all entries ... be given serious consider-
ation. . . ." Bellarno, 678 F. Supp. at 415 n.6 (emphasis added).
The import ban readily may be distinguished from a general statement of
policy. The latter provides guidelines for future action and does not "have a sub-
stantial impact on those regulated." United States v. Articles of Drug, Consisting
of: 203 paper bags, more or less, Nos. 84C7677, 85C1879 & 85C6020, 1986 WL
3104, at *12 (N.D. Ill. Mar. 18, 1986) (quoting Aiken v. Obledo, 442 F. Supp. 628,
649 (E.D. Cal. 1977)); see also Panhandle Producers and Royalty Owners Assoc. v.
Economic Regulatory Administration, 822 F.2d 1105, 1110 (D.C. Cir. 1987) (a "poli-
cy statement cannot create a norm binding the promulgating agency or its dele-
gate[s]").
.48 New York v. Lyng, 829 F.2d 346, 354 (2d Cir. 1987) (stating that interpreta-
tive rule does not change existing rules and obligations); Noel v. Chapman, 508
F.2d 1023, 1030 (2d Cir. 1975) (notice and comment required if regulations have
"substantial impact on those regulated").
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determination concerning importing a small quantity of RU
486 for her personal use.149 The import alert extinguished
this right.15 Therefore, applying the Bellarno court's reason-
ing, it is apparent that the FDA promulgated a legislative
regulation when it issued the RU 486 import ban under the
guise of its enforcement power. Since the FDA failed to provide
notice to the public by publishing the proposed alert in the
Federal Register and neglected to provide an opportunity for
the public to comment and participate in the rulemaking pro-
cess, it violated the procedural requirements of the APA."'
.. Benten v. Kessler, 799 F. Supp. 281 (E.D.N.Y. 1992). Judge Sifton held that
the FDA had taken away an existing right by imposing the import ban:
The government . . . argues that no obligation was created by the alert
as (1) the plaintiff never had any right to import RU 486 for personal
use, and (2) the alert did not create new duties. As to the first, the
government focuses on the wrong right. It argues that, since there was
never a statutory right to import RU 486, the alert took nothing away.
The right at issue, however, was that created . . .by the revision of the
R[egulatory] Pirocedures] M[anual]. Under the RPM, plaintiff had a right
to a case-by-case discretionary decision by the FDA on her personal im-
portation of RU 486. After the ban this right no longer existed.
Id. at 289 (emphasis added); see also Homemakers North Shore, Inc. v. Bowen,
832 F.2d 408, 412 (7th Cir. 1987) ("when an agency gets out the Dictionary of
Newspeak and pronounces that for purposes of its regulation war is peace, it has
made a substantive change for which the APA may require procedures").
1"O One commentator writes on the danger of permitting agencies to rewrite
their own rules without following the APA requirements:
[If an agency issues] legislative regulation . . .directly affecting conduct
of agency personnel and members of the public . . . it may not subse-
quently repudiate that announced meaning and substitute for it a totally
different meaning without proceeding through notice and comment
rulemaking normally required for amendments of a rule. To sanction any
other course would render the requirements of § 553 basically superfluous
in legislative rulemaking by permitting agencies to alter their require-
ments for affected public members at will through the ingenious device of
"reinterpreting" their own rule.
Michael Asimow, Nonlegislative Rulemaking and Regulatory Reform, 1985 DUKE
L.J. 381, 396.
... Nor can the .FDA avoid the notice and comment process and sustain the
import ban by invoking the "good cause" exception. 5 U.S.C. § 553(b)(B) (1986).
There is nothing in the administrative record to indicate that the required notice
and comment procedure was "impracticable, unnecessary, or contrary to the public
interest." Id. 553(b)(A). The FDA has not demonstrated that there is a compelling
public interest justifying an immediate import ban on RU 486. Conversely, the
public had expressed an interest in the drug, forwarding numerous inquiries about
the medical applications of the drug to the FDA, and it should have had an op-
portunity to comment on any proposed ban. Yet the FDA dismissed the public's
right to comment on proposed rules before those rules were enacted without show-
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The district court, therefore, correctly characterized the FDA's
actions as "illegal."152
C. An Arbitrary and Capricious Regulation
Even if the import ban on RU 486 was an interpretative
rule not subject to notice and comment procedures, a court
nevertheless could properly invalidate it as arbitrary and ca-
pricious. Since there was no administrative record on which to
base a decision to ban the import of RU 486, the FDA's action
was ill-considered. Moreover, the FDA treated RU 486 differ-
ently under the personal use policy depending on how the drug
was to be used. A brain cancer patient was able to obtain RU
486 less than four weeks after Ms. Benten was denied access
to the drug, even though the import ban remained in force.15
Also, the agency allowed the importation of a number of unap-
proved drugs that posed a known health risk to users. 54
ing that urgent circumstance required the agency to "eliminate a valuable proce-
dure." Williams v. Pierce, 708 F.2d 57, 62 (2d Cir. 1983) (Mansfield, J., dissent-
ing), cert. denied, 464 U.S. 1046 (1984); see Chrysler Corp. v. Brown, 441 U.S. 281,
316 (1978) ("notions of fairness and informed administrative decision making re-
quire that agency decisions be made only after affording interested persons notice
and an opportunity to comment."). The prescribed notice and comment process was
not impracticable because no one had promoted RU 486 in the United States such
that the imposition of an immediate import alert would be necessary. Letter from
Acting FDA Commissioner James Benson to Representative Ron Wyden (June 29,
1990). Additionally, Americans, especially American women, have a strong (public)
interest in RU 486 as an alternative to surgical abortion. For instance, French
officials have recognized the importance of the drug by referring to it as the "mor-
al property" of women. See supra notes 1 & 10.
..2 Benten, 799 F. Supp. at 283.
"' Associated Press, Cancer Patient Can Get Unapproved Abortion Pill, N.Y.
TIMEs, July 30, 1992, at A22. The medical condition of the patient in this case
does not legitimize the agency's disparate treatment of RU 486 based on the speci-
fied medical use. The FDA appropriately used its regulatory discretion in accor-
dance with the personal use exception to benefit this critically ill patient. It con-
sidered the facts of an individual's predicament to determine whether access to the
drug should be granted. Ms. Benten sought the exact same determination, but in
her case the FDA refused to evaluate the facts of her situation and rested its
decision on the existence of the import alert.
... See infra notes 184-86 and accompanying text.
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1. Scope of Judicial Review of Agency Action
The district court correctly held that the FDA's action
imposing the import ban is subject to review by the courts155
because it had not been committed to agency discretion by
law.'56 The FDA's action may be criticized as "arbitrary, ca-
pricious, [and] an abuse of discretion.""7 This test, set forth
in the APA, defines the limits of the FDA's discretion by pro-
viding a standard of review for courts evaluating the FDA's
policies and rulemaking. The scope of review under the "arbi-
trary and capricious" analysis, however, is quite narrow.158
The court must show deference to agency determinations and
actions, and it should not "substitute its judgment for that of
the agency."'59 Nevertheless, if an agency acts, it must be
able to provide concrete reasons for why it did so, and the
actions must be logically consistent.60 Courts are free to ex-
amine the record for errors of procedure, 6' to identify wheth-
er the agency has followed its own guidelines'62 and to en-
"' The FDA argued in Benten v. Kessler that the import alert is not subject to
judicial review as enforcement action, that public health and safety concerns legiti-
mize the import ban and that the district court usurped the role of the FDA by
substituting its judgment for that of the agency. Notice of Appeal, Civ. No. 92-
3161, U.S. Attorney E.D.N.Y., Summary of Argument, July 14, 1992 (on file with
the Brooklyn Law Review). The government relied upon Heckler v. Chaney, 470
U.S. 821 (1980), and interpreted it broadly. See supra note 122 and accompanying
text. Even if an agency action creates no direct obligation, is informational and
does not involve enforcement or a formal effect, it is nevertheless subject to judi-
cial review. Citizens Communication Ctr. v. FCC, 447 F.2d 1201 (D.C. Cir. 1971)
(court applied a test examining the fitness for judicial review and the hardship to
the parties attendant to withholding judicial consideration in determining if an
FCC policy statement was ripe for review).
16 Citizens to Preserve Overton Park v. Volpe, 401 U.S. 402, 410 (1971); see
supra notes 71-77 and accompanying text.
117 5 U.S.C. § 706(2)(A) (1986).
158 Motor Vehicle Mfrs. Ass'n v. State Farm Mut. Auto. Ins. Co., 463 U.S. 29,
30 (1983) (National Highway Traffic Safety Administration's decision to rescind a
prior regulation remains subject to the arbitrary and capricious test).
159 Id.; see also Chevron, U.S.A. v. National Resource Defense Council, 467 U.S.
837 (1984) (stating that agency interpretation of statue must be logical).
16o Motor Vehicle, 463 U.S. at 42; see also Public Citizen v. Heckler, 653 F.
Supp. 1229, 1240 (D.D.C. 1987) (Department of Health and Human Services re-
fusal to issue regulations banning the interstate sale of unpasteurized milk arbi-
trarily ignored record demonstrating existence of serious health risk).
161 Id.
162 Heckler v. Chaney, 470 U.S. 821, 831 (1985); Williams v. Pierce, 708 F.2d
57, 64 (2d Cir. 1983) ("[I]t is well settled that regulations promulgated under stat-
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sure that the agency can provide factual grounds for its
decisiomnaking.'63 "If the agency cannot articulate a policy
that justifies its action or demonstrate the consistency of its
action with existing agency policy, Congress has not authorized
the action.... Denying the appropriateness of a court's
role... [in requiring such a response would] result in 'an
impoverished judicial role indeed."" 4
Courts have commented upon the need for a sufficient
administrative record upon which to base administrative agen-
cy regulations and decisions.'65 For example, in Ethicon, Inc.
v. Food and Drug Administration, the court held that where
the FDA sought to reclassify medical devices relying on "volu-
minous materials" and "hundreds of studies" and created a de-
tailed administrative record, the FDA's action could not be
characterized as arbitrary and capricious. 6 ' The Ethicon
court reasoned that the central issue to be determined is
whether there was a record to support the agency's classifica-
tion decision. It would not extend the scope of judicial review
to assess the validity of the conclusion itself. In its view, even
if a plaintiff argues that the FDA's conclusion itself is wrong
based on the substance of the record, the court may not review
the FDA's decision. 67 The Ethicon court's view of its limited
role assures that administrative agencies will have wide dis-
cretion. Notwithstanding Ethicon's rationale, a necessary part
of a court's assessment of whether an agency decision is arbi-
trary or capricious depends on evaluating whether a decision
utory authority have the force and effect of law . . . an agency is bound by its
own formal, published regulations that protect the important rights of the public."),
cert. denied, 464 U.S. 1046 (1984), rehearing denied, 465 U.S. 1055 (1985).
'" Upjohn Mfg. Co. v. Schweiker, 681 F.2d 480 (6th Cir. 1982) (finding that
FDA undertook fact finding procedures and created a detailed record and, thus,
did not act arbitrarily).
'' Shapiro & Glicksman, supra note 60, at 867-68.
165 "Administrative record" in this context refers to a body of evidence contain-
ing internal documents such as correspondence, memoranda or reports and exter-
nal documents including scientific studies and manufacturer's information which
provides the basis for FDA decisions. This material may or may not be published
or available to the public.
1" 762 F. Supp. 382, 387-89 (D.D.C. 1991). "It is clear that this record, replete
with substantial, valid scientific evidence, more than adequately supports the
agency's determination that there exists sufficient information to characterize and
understand the generic class . . . and to establish the safety and effectiveness or
these devices." Id. at 389.
7 Id. at 387.
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reasonably follows from the administrative record." Similar-
ly, in National Association of Pharmaceutical Manufacturers v.
Department of Health and Human Services, a suit involving
the FDA's proposed regulations for the manufacture of drugs,
the court defined an adequate administrative record as one
that offers a "thorough and comprehensible statement of the
reasons for [the FDA's] decision.""6 9 The National Association
court explicitly required the FDA to demonstrate a reasoned
basis for its decision to take regulatory action stating, "[Tihe
agency must explain the basis for its actions."'7 ° The court
held that the administrative record explaining the proposed
regulations, containing summaries of the FDA's enforcement
and inspection reports, and including 2000 pages of public
comments and a 306 page FDA response to these comments
was satisfactory. The record also included documents reflecting
the FDA's meetings with industry and educational groups.' 7'
These cases suggest that when the FDA articulates reasonable
reasons for its decisions and documents its reasoning, courts
should defer to its judgment. In the absence of an administra-
tive record, however, courts are not so indulgent of an agency's
discretion.
2. Insufficient Evidence to Support the Import Ban
The Benten court pointedly asserted that no administrative
record was put before the court and that it was "unlikely that
any such record exists."72 Thus, the FDA acted improperly
by issuing an import ban prior to assembling an administrative
file upon which to base an enforcement decision. The absence
16 See supra note 158.
16 National Ass'n of Pharmaceutical Mfrs. v. Department of Health and Human
Servs., 586 F. Supp. 740, 756 (S.D.N.Y. 1984) (quoting National Nutritional Foods
Ass'n v. Weinberger, 512 F.2d 688, 701 (2d Cir. 1975), cert. denied, 423 U.S. 827
(1975)).
170 Id. at 755:
171 Id.; see also Synthetic Organic Chem. Mfrs. Ass'n v. Secretary, Dep't of
Health and Human Services, 720 F. Supp. 1244, 1257 (W.D. La. 1989) (finding
that agency's classification and subsequent publication of certain carcinogens-was
based on extensive laboratory studies by agency scientists and was not arbitrary
or capricious); Upjohn Mfg. Co. v. Schweiker, 681 F.2d 480, 483 (6th Cir. 1982)
(FDA's factfinding procedures concerning safety and efficacy of newly approved
drug were "stated in detail.... Nothing more [was] required.").
172 Benten v. Kessler, 799 F. Supp. 281, 290 (E.D.N.Y. 1992).
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of any administrative record creates a presumption that the
action taken is arbitrary and capricious. To defeat Ms.
Benten's claim that the import ban was arbitrary and capri-
cious, the FDA had to support its rationale with a record. Yet
the government was unable to produce an administrative file
on RU 486.1" According to the FDA's response to a compre-
hensive Freedom of Information Act ("FOIA") request dated
February 1991, the FDA had not investigated whether the
drug posed a safety risk, had not identified any ongoing stud-
ies that made such an assertion and was not aware of any
injuries that had resulted from the drug's use in this coun-
try.
174
Since the broadly worded FOIA request covered any rele-
vant documents in FDA's possession, whether the documents
were generated by the Agency, by a member of the Bush ad-
ministration or other persons, any safety concerns the FDA
173 When considering the administrative record, the "focal point for judicial re-
view should be the administrative record already in existence." Camp v. Pitts, 411
U.S. 138, 142 (1973) (arbitrary and capricious test applied to Comptroller of
Currency's denial of National Bank Charter). The court must compare the record
and the reasons the agency offered. Benten, 799 F. Supp. at 290.
17 Letter from Julie Mertus, Attorney, American Civil Liberties Union Repro-
ductive Freedom Project, to Freedom of Information Staff, FDA (Feb. 6, 1991)
(attached to Order to Show Cause with Temporary Restraining Order, Benton (No.
CV-92-3161)). Despite a letter with over sixteen specific inquiries probing the con-
tents of such an administrative record, the response letter from FDA's Center for
Drug Evaluation and Research stated that "[w]e have searched our files in the
Center for Drug Evaluation and Research and cannot locate any document which
would be responsive to your request with regards to your items 1, 2, 3, 4, 5, 6, 8,
10, 11, 12, 13, 14, 15, 16, and 17." Letter from Eulah M. Jones, Lead FOI Techni-
cian, Center for Drug Evaluation and Research, FDA to Julie Mertus, Attorney,
American Civil Liberties Union Reproductive Freedom Project (Mar. 12, 1991) (on
file with the Brooklyn Law Review). The Center for Drug Evaluation and Research
is the unit of the FDA responsible for providing scientific and other documentation
to FDA officials to assist administrative decisionmaking. Telephone Interview with
Fredda Shere-Valenti, Division of Import Operations and Policy, FDA (Oct. 6,
1992). If this division of the FDA possessed no relevant documents concerning RU
486, it is difficult to imagine who in the agency had such information.
The Center for Drug Evaluation and Research's response left only requests
Nos. 7 and 9 to the Import Operations Branch, the enforcement branch of the
FDA. The Import Operations Branch then replied, providing the letters written by
Senators encouraging a ban on RU 486 importation in response to request No. 9
and indicating that "According to our Import Operations Branch, FDA does not
have any information concerning item No. 7 of your request." Letter from Terry L.
Roseby, Consumer Safety Officer, Office of Enforcement, FDA to Julie Mertus,
Attorney, American Civil Liberties Union Reproductive Freedom Project (Mar. 7,
1991); see supra notes 11-46 and accompanying text.
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might have had involving RU 486 would have been supported
by documents. As the Benten court noted, "The FDA is re-
quired by its own regulations to preserve complete files of the
bases of 'every significant FDA decision on any matter under
the laws administered by the Commissioner, whether it is
raised formally, for example, by a petition, or informally, for
example, by correspondence.""" The absence of any relevant
documents in FDA files relating to deliberations about safety,
possible importations or examples of RU 486's use in this coun-
try implies a single undisputed conclusion: the FDA did not
issue the automatic detention order for RU 486 based on any
substantive research or independent investigations.'
Even if some of these documents, such as internal memo-
randa, may have been unavailable through a FOIA request
because the FDA could invoke agency privilege, the language
of the request was sufficiently broad to require, at the very
least, that the agency identify such documents and state that
it was withholding them.' Yet the response letters from the
175 Benten, 799 F. Supp. at 290 (citing 21 C.F.R. § 10.70 (1993)).
176 Several commentators have affirmed this conclusion. One family planning
expert has asserted that "Federal officials have ... stated that. . . the alert
was . . . imposed for political reasons only. . . ." Klitsch, supra note 1, at 280.
This conclusion is echoed by Counsel to the Subcommittee on Regulation, Business
Opportunities, and Energy of the House of Representatives' Committee on Small
Business, Graydon Forrer. Telephone Interview with Graydon Forrer, supra note
12. Mr. Forrer characterized the import ban as motivated by "purely political"
concerns. Id. The Subcommittee's Chairman, Representative Ron Wyden, has held
hearings on FDA's decision to impose the import ban on RU 486. See supra note
4. When the Subcommittee attempted to subpoena documents reflecting the FDA's
decisionmaking on RU 486, the FDA was cooperative but did not supply any docu-
ments that reflected a scientific basis or other apolitical reason to exclude imports
of RU 486. Id. Moreover, no other evidence has surfaced to suggest that the agen-
cy was motivated by concerns for the health and safety of the public when it
imposed the import ban. In the absence of an administrative record, it is unclear
what specific events prompted the first FDA action taken by the Director of Field
Operations in September 1988, imposing the ban on RU 486. See supra note 110.
If viewed in context with the letters from conservative members of Congress, how-
ever, the second agency action against the drug, in June 1989 seems to be in
response to such criticism. See supra note 111. Indeed, such letters may have been
highly persuasive to political appointees in the FDA responsible for setting RU
486 policy. The imposition of a revised, more specific import alert was consistent
with the Bush Administration's stance on abortion.
.. Administrative agencies have a well-recognized privilege with respect to
internal documents regarding administrative decisionmaking. The policy behind
this privilege is the agency's interest in its ability to make both routine and con-
troversial decisions free of undue or inhibiting public scrutiny. This privilege, how-
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FDA's Center for Drug Evaluation and Research and the Office
of Enforcement suggest that no internal documents concerning
the safety, risks or importation of RU 486 existed. Without an
administrative record to support its imposition of the import
ban on RU 486, the FDA's action was, as a matter of law, arbi-
trary and capricious.'78
Since the FDA did not provide the court with an adminis-
trative record that could illuminate the agency's consideration
of the risks associated with RU 486 and the reasons that led
them to ban all unapproved abortafacients, it is difficult for
critics to assess the FDA's rationale and characterize it as
reasoned. One could look to the agency's own regulations to
evaluate the import ban according to the FDA's articulated
standard. An agency is "bound to follow procedures required by
its own regulations."179 In considering whether an import ban
should have been imposed, the FDA was obligated to follow its
own "Policy Guidance for Personal Importation of Unapproved
Drugs" and to assess the risk of permitting importation.'
Under this standard, the FDA evaluates four factors to deter-
mine if the importation of an unapproved drug should be per-
mitted for personal use. These factors include: whether the
banned drug poses a substantial health risk, whether a com-
mercial black market exists for the drug, whether other per-
sons have attempted to import the drug and whether the drug
would be used with physician supervision.
Upon considering each of these factors, the FDA's safety
rationale for imposing an import ban on RU 486 still appears
arbitrary, capricious and wholly insupportable. Large-scale
clinical studies on the safety and efficacy of the drug contradict
the FDA's conclusion that the importation of RU 486 would
result in a substantial health risk to the public. 8' In fact,
during oral argument on the preliminary injunction in Benten
v. Kessler, counsel for the FDA and the Customs Service
seemed to have few reservations about the safety of the
ever, does not relieve an agency of its legal obligation to indicate to the requester
that it is withholding documents on that basis.
... Benten, 799 F. Supp. at 288.
... Id. at 290.
" See supra notes 97-106 and accompanying text.
... See supra notes 11-31 and accompanying text.
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drug.182 Indeed, counsel even suggested that Leona Benten
leave the country to take the medication on an airplane much
as one might take aspirin or other over-the-counter medica-
tion. 8
3
While the medical benefits and safety of RU 486 are not
disputed by scientific studies, the first factor the FDA should
consider, there remains a question of whether a black market
currently exists for the drug-the second factor evaluated by
the FDA. Indeed, the FDA's concern about unsupervised use,
while legitimate, is not sufficiently persuasive to warrant the
imposition of the ban, since the FDA and Customs agents un-
der the personal use exception evaluate each application. Case-
by-case determinations provided for by the personal use regu-
lation would serve to protect the health of importers. Customs
agents and FDA personnel could require proof that the import-
er will use the drug while under the care of a physician and
will not resell the drug. Also there is no existing evidence sug-
gesting that the personal importation of RU 486 will spur the
growth of a black market. Since there is no underground traffic
in RU 486 currently, and since no one had ever attempted to
import the drug prior to July 1992, RU 486 would have met
the second and third criteria for personal importation set forth
by the FDA's "Policy Guidance."
To the extent that the health risk might be greater if RU
486 was obtained on a black market and taken without a
doctor's supervision, the fourth factor, this danger exists with
other drugs that the FDA has permitted to be imported for
personal use. For example, the FDA has permitted HIV-posi-
tive patients to import at least two unapproved drugs of ques-
tionable merit. The agency allowed the unapproved drug Com-
pound Q to be imported for personal use, sold on the black
market and tacitly approved large-scale human trials." Al-
though this drug was linked to a number of deaths and its
users experience severe symptoms ranging from partial paraly-
sis to temporary blindness, the FDA waited more than a year
to issue an import alert."8 5 Similarly, the anti-viral drug, dex-
182 Benten, 799 F. Supp. at 281.
183 Id.
1" Myers, supra note 100, at 330.
18 Id. at 310.
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tran sulfate, was popular with AIDS patients, who had import-
ed it for their personal use." The FDA issued an automatic
detention order for dextran sulfate only when studies demon-
strated that it was ineffective. The ease with which AIDS pa-
tients were able to import Compound Q and dextran sulfate is
in stark contrast to the FDA's quick action to impose the im-
port ban on RU 486, a much safer and more effective drug
than either of these examples. This contrast suggests that FDA
decisions regarding importation are not based primarily on
health and safety concerns and that drugs that may induce
abortions will be subject to disparate treatment. Nor can these
examples be distinguished from RU 486 by arguing that termi-
nally ill patients should have greater access to unapproved
drugs. There is no requirement in the personal use exception
that requires one to have a serious illness to import unap-
proved drugs for one's personal use.
At least one commentator has addressed the FDA's con-
cerns about persons who would use an unapproved drug with-
out a doctor's supervision."7 Since "prohibition of a prod-
uct..., must be a last resort for the state as it constitutes a
complete abrogation of choice," the FDA must rely on the exist-
ing system of limited access to potent drugs through the use of
prescriptions and licensed pharmacies to protect the safety of
the public. 8 It is not enough that the potential for misuse by
the public exists; rather, the question is whether a distribution
system is in place to safeguard against such misuse. Other
approved drugs pose substantially greater health risks to the
public than certain unapproved drugs, and by restricting their
availability to "prescription-only," the FDA's interest in public
health and safety is met."9
In summary, the conclusion that the FDA acted in an
arbitrary and capricious manner appears indisputable. Not
only did the FDA evaluate the drug without assembling an ad-
ministrative record of any kind, it immediately imposed an
absolute ban on a safe and effective chemical alternative to
... Id.; see also Wendy Y. Mariner, Equitable Access to Biomedical Advances:
Getting Beyond the Rights Impasse, 21 CONN. L. REv. 571, 574-75 (1989).
" Elizabeth G. Patterson, Health Care Choice and the Constitution: Reconciling
Privacy and Public Health, 42 RuTGERS L. REV. 1, 2 (1989).
''Id. at 82.
' Id. at 45.
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surgical abortion, while permitting other, more dangerous
drugs to be imported. In addition, the FDA's regulatory re-
sponse to RU 486 seems particularly untenable when the FDA
excludes the drug if it will be used to terminate a pregnancy
but permits the drug to be imported for personal use as an
anti-cancer agent.
III. SociAL AND LEGAL DEVELOPMENTS INVOLVING RU 486:
IDEAS TO CONSIDER
Much of this Note has been devoted to exploring the poten-
tial medical uses of RU 486, explaining the role of the FDA as
a regulatory body, exploring why the FDA imposed the ban on
imports of RU 486 and evaluating whether the district court
correctly decided that the agency wrongly denied Ms. Benten
access to RU 486."9° What may be lost in the retelling of Ms.
Benten's story, however, are the broader implications for our
system of participatory government that these events suggest.
RU 486 and the Benton case provide an opportunity to
critique existing law and judicial decisions, and to consider and
challenge the level of institutional attention to and financial
support for research on women's health care needs and deliv-
ery of services by governmental agencies, government-spon-
sored research programs and the medical establishment. 9'
Perhaps Ms. Benton's attempt to obtain RU 486 would have
been aided had FDA regulations provided different avenues for
asserting her interest in the drug to substantiate her claim.
Procedural regulations that permit for notice and comment
periods are closely circumscribed vehicles for gathering infor-
mation. It is not clear that even existing notice and comment
1" See also Csilla Muhl, RU-486: Legal and Policy Issues Confronting the Food
and Drug Administration, 14 J. LEGAL MED. 319 (1993) (survey of debate concern-
ing the FDA's import ban on RU 486).
191 Legal scholarship in recent years has turned to examining "outsider" nar-
ratives to explore the role of law and to examine judicial decisions. Critical legal
scholars argue that storytelling in legal journals provides a means to communicate
with lawmakers and adjudicators in a professional voice through an accessible
medium. Then, the act of presenting alternative, non-hegemonic narratives becomes
a means to effect law reform. For a discussion of the importance of storytelling,
see Richard Delgado, Storytelling for Oppositionists and Others: A Plea for Narra-
tive, 87 MICH. L. REV. 2411 (1987).
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procedures ensure that interested persons have an opportunity
to influence the development of FDA policy in a meaningful
way. Therefore, one must ask, how can the FDA and, ultimate-
ly, Congress ensure that there is a meaningful notice and com-
ment process as it currently exists?
One answer is to have Congress write enabling legislation
to encourage greater judicial review of agency action as a final
safeguard for the public interest. But that may not be realistic.
Perhaps, then, the judiciary must stake out a greater role in
curbing the discretion of administrative agencies if Congress is
unable or unwilling to do so. The Benten case suggests that
currently the judicial system, with the exception of the District
Court for the Eastern District of New York, is willing to sanc-
tion broadly sweeping discretionary powers for an agency even
on highly controversial questions. Ms. Benten's predicament
dramatized how difficult it may be in the future both to en-
courage an agency to hear a politically sensitive point of view
and to confront agency actions in court, even when a legal
challenge reflects the interests of a less politically powerful
group.
A. Silence and Participation-Women's Health Care
Both judicial review and a determination that a period of
notice and comment pursuant to the APA was required were
essential in this case in order to ensure that there was an
opportunity for women seeking to import RU 486 to communi-
cate with the FDA. After the Benten decision, however, in the
absence of a formal communication mechanism other than the
formal notice and comment procedure, the FDA was free to
ignore the loud clambering of the public outside of agency
walls.'92 Permitting an agency to avoid responding to public
"2 One commentator suggests that one way to ensure that the public has an
opportunity to comment on FDA policies that impact their lives would be to sup-
plement existing APA rules governing procedures the FDA must follow when issu-
ing regulations. Debora C. Fliegelman, Comment, The FDA and RU 486: Are Poli-
tics Compatible with the FDA's Mandate of Protecting Public Health and Safety?,
66 TEMP. L. REv. 143, 144 (1993) (the imposition of the ban on RU 486 was a
political action). By requiring the FDA to file an impact statement similar to the
environmental impact statement required of developers, the public would be able
to assess the scientific basis for specific rulings. Presumably, these procedures
could require the FDA to articulate what impact its decisions would have on dif-
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comment in this way is both shortsighted and frighteningly
undemocratic.93
For many, the outcome of this case was particularly frus-
trating precisely because issues of women's health historically
have been largely ignored by the Department of Health and
Human Services. Within the Department, both the National
Institutes of Health ("NIH") and the FDA have particular in-
fluence on American lives whether through identifying re-
search priorities or regulating one-fourth of all consumer prod-
ucts sold in the United States."M Women's health advocates
have struggled for two decades to encourage government offi-
cials and researchers to include women in research and drug
protocols in order to assess how diseases manifest themselves
ferent populations affected by the regulation. Such a procedural requirement would
provide greater notice to interested persons while assisting the public's ability to
understand a regulation by encouraging the FDA to disclose its view of the scope
of a regulation's impact.
As proposed, this additional procedural safeguard will not sufficiently con-
strain the FDA from arbitrary decisionmaking. First, if the proposed regulations
are submitted to representatives in the medical community, the narrowness of the
consulted group becomes an issue. Surely, gathering the comments of a medical
body should not substitute for an open process where any potentially affected
person could comment. Women should be able to speak directly to the agency
through oral or written submissions. The importance of an open process with wom-
en speaking their own truths is particularly important precisely because of the
history of the agency's inattention to women's health concerns.
Second, even if the FDA does spell out more carefully the evidentiary basis of
a decision and its vision of how a regulation may impact a particular group's
health, nothing in this proposal suggests that the FDA must draw unbiased con-
clusions after a thorough evaluation of a regulation's impact. The process as envi-
sioned is more rigorous and time-consuming but still leaves the FDA subject to
political influence. The FDA's impact statement could easily reflect political bias
and, thus, would be little more than a standard policy paper.
Since women's perspectives on RU 486 and other health issues particular to
women have been generally absent from debates about health care, and if addi-
tional procedural requirements would not ensure that the FDA acts free from
undue political pressure, then the importance of judicial review becomes even
clearer.
" See Crittenden, supra note 80; McGarity, supra note 84.
1' Orrin G. Hatch, The Future Direction of the Food and Drug Administration,
48 FOOD DRUG COSM. L.J. (15) (1991):
Today, the FDA covers a greater portion of our lives than ever envi-
sioned by writers of the Federal Food, Drug, and Cosmetic Act. The FDA
is responsible for regulating more than $700 billion worth of goods sold
annually to Americans; that constitutes about twenty-five percent of the
total expenditures for personal consumption in the United States each
year.
1596 [Vol. 59:1551
FUNDAMENTAL RIGHT OF ACCESS TO RU 486?
in women and to determine how women respond to treatment.
Until 1990, NIH grantees routinely excluded women from
studies. 9 ' Although the leading causes of death for women
are heart disease, cancer and strokes, the prototypical study
population has been overwhelmingly male, with study results
applied to women.'96 The medical establishment has been
widely criticized in recent years for its willingness to diagnose
and treat women based on research studies involving men
only. For example, a landmark study used 20,000 male sub-
jects to determine if the use of aspirin decreased the likelihood
of heart attacks. Although almost one-half of all heart attack
victims are female, no women were included in a study, the
results of which will continue to guide treatment of wom-
en.
197
Other examples of gender bias influencing research priori-
ties and project design have been documented. For instance,
researchers interested in women's health issues had difficulty
securing funding; in 1990, a five-year, comprehensive $50-mil-
lion breast-cancer study was tabled for budgetary reasons,
although a fifteen-year $142-million study involving lowering
cholesterol in men had recently concluded. 9 ' Critics have al-
so noted that bias infects studies when researchers conceptual-
ize women's health care research only as "reproductive" and
"all other."'99 From this evidence of gender bias in medical re-
search, health care professionals have concluded that women's
health needs must be addressed through further research into
' For a comprehensive statement of NIH's planned response to gender dispar-
ities in research and treatment, see Bernadine Healy, Women's Health, Public
Welfare, 266 JAMA 566 (1991) (Ms. Healy was the first female director of the
NIH). See also Bernadine Healy, Women's Health is Our Modern-Day Suffrage
Movement, 110 LADIES HOmE J. 138 (1993) (interview with Dr. Healy, given after
she left the NIH post, providing opportunity for her to reflect on her contributions
as director).
196 See Vivian W. Pinn, Women's Health Research: Prescribing Change and Ad-
dressing the Issues, 268 JAMA 1921 (1992) (editorial commenting on need for
greater attention on women's health issues).
19 See Joanne Silberner, Health: Another Gender Gap: A Crackdown on Re-
search Bias Against Women Should Produce Change, U.S. NEWS & WORLD REP.,
Sept. 24, 1990, at 54.
"' Id.
19 See Carolyn M. Clancy & Charlea T. Massion, American Women's Health
Care: A Patchwork Quilt with Gaps, 268 JAMA 1918 (1992) (description of impedi-
ments to health care for women).
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women's health issues. Without a scientific base of knowledge
based on research on women, current therapies may be ineffec-
tive or even harmful.
In addition to affecting medical research projects, gender
bias has negative effects on the testing for, and diagnosis and
treatment of, disease in women. Studies demonstrate that
there are disparities in women's access to diagnostic proce-
dures and that therapeutic intervention is more available to
men than to women."0 For instance, women are less likely to
receive transplants, kidney dialysis and coronary bypass sur-
gery than men.20' Equally troubling is evidence suggesting
gender bias in clinical decisionmaking. Doctors are more likely
to attribute women's health complaints to psychological causes
than physical ailments.0 2 The growing presence of female
doctors may help diminish some gender discrimination in the
clinical setting. At least one study suggests that female physi-
cians spend more time with female patients and encourage
patient participation.0 3  Although female professionals
groomed by the medical establishment may bring gender bias
to their practices, if women are encouraged to participate more
actively in discussions of their health care needs, presumably
more of their needs will be met.
In response to evidence of systemic gender bias in the
medical system, a number of reform proposals-institutional,
legislative, and research plans-have been initiated by differ-
ent entities. Among the agencies, the NIH, in 1990, created an
"Office of Research on Women's Health" to "address inequities
in women's health research." 4 Also, members of Congress,
particularly female legislators, have sponsored legislation de-
signed to attack the problem of inadequate resources and to
draw to attention to women's health issues.205 Women's advo-
200 For an excellent editorial describing gender bias in diagnoses and treatment,
see Gender Disparities in Clinical Decision Making, 266 JAMA 559 (1991). To
consider the question of gender discrimination in the mental health context, see
D'Vera Cobn, UPI, The Psychological Gender Gap: Women's Health Needs are Often
Ignored, Experts Say, WASH. POST, Jan. 16, 1985, at Z19.
201 Gender disparities, supra note 200, at 559.
202 Id.
203 See generally Clancy & Massion, supra note 199.
204 Pinn, supra note 196, at 1921.
205 See Omnibus Women's Health Legislation Package, THE GRAY SHEET, Sept.
20, 1993, at 24-25 (FDC Reports); THE BLUE SHEET, Sept. 15, 1993, at 14-16 (FDC
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cacy on behalf of women's health seems to have had some
effect: there is a push among researchers to remedy the exist-
ing lack of scientific knowledge of women's health issues. In
1993, the NIH awarded the first research contract to launch a
$625 million, fifteen-year comprehensive study of women's
health issues."6 Research alone, however, will be not allevi-
ate gender bias in the health care system. Even as researchers
begin to consider women's health issues, many health care
professionals argue that a more systemic approach is necessary
to eliminate gender discrimination. They advocate greater
emphasis on women's health in medical training-now limited
to obstetrics and gynecology-and seek ways to encourage
more women to become faculty members and researchers." 7
Thus, part of the story of RU 486 is that the FDA's dispa-
rate treatment of the drug marks another chapter in the trou-
bling history of women's health policy at the national level. In
light of this history, women's interest and participation in
policymaking about women's health issues should be encour-
aged. Yet by imposing the alert and characterizing it as inter-
nal policy rather than a substantive rule, the FDA avoided
involving women in a crucial decisionmaking process. There-
fore, at a time when the health care establishment agrees that
it wants to encourage greater discussion on women's health
issues, the FDA simply refused to engage in dialogue with
women concerning RU 486, effectively silencing women's voic-
es. The courts should have ensured that women's participation
and comments concerning RU 486 were at least solicited before
upholding the FDA's discretion to ban its import for personal
use.
Reports).
" See U.S. Dept of Health and Human Services, NIH Launches Largest Study
of Women's Health, 108 PUBLIC HEALTH REP. 258 (1993); see also Paul Cotton,
Women's Health Initiative Leads Way as Research Begins to Fill Gender Gaps, 267
JAMA 469 (1992); Ruth Kirschstein, Largest US Clinical Trial Ever Gets Under
Way, 270 JAMA 1521 (1993).
" For summary of proposed medical school curriculum changes and conference
proceedings regarding the creation of a women's health specialty, see Andrew A.
Skolnick, Women's Health Specialty, Other Issues on Agenda of "Reframing" Confer-
ence, 268 JAMA 1813 (1992).
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B. Looming Constitutional Questions
It is particularly ironic that the FDA would seek to limit
debate concerning a class of drugs, the antiprogestins, that will
raise unique constitutional questions. In a democratic society,
citizens should expect that when scientific developments prom-
ise to have important legal, political and social implications,
procedural safeguards that ensure an inclusive process and
communication would be enforced rather than dismissed as
unimportant.
The simultaneous development of RU 486 as both a birth
control method and an abortifacient presents a factual circum-
stance that challenges existing constitutional jurisprudence on
rights of access to birth control and abortion services. Presum-
ably some states will seek to limit access to the drug. States
could try to regulate the drug as either a birth control method
or an abortifacient, since it is likely that the drug eventually
will be available for both uses.0 8
In response to these efforts, women who want to use the
drug for either purpose will have at least three legal argu-
ments to assert. First, since the FDA will have approved the
drug for use as an abortifacient and, probably, limited access
through a by-prescription-only requirement, women may argue
that the federal regulatory scheme, as administered by the
FDA, has preempted further state action restricting distribu-
tion of the drug." 9 Second, women may assert that restric-
208 See Part I.A., supra.
209 The Supreme Court set forth three means by which federal legislation pre-
empts state law on the same subject in Pacific Gas and Elec. v. State Energy
Resources Conservation Comm'n, 461 U.S. 190, 203-204 (1973) (when a state, as-
serting economic motives, sought to impose a moratorium on building new nuclear
plants until a permanent disposal system for nuclear waste could be developed,
preemption doctrine did not apply; federal law only occupied the field of nuclear
safety regulation). Additional state regulations are impermissible: (1) if Congress
has expressly preempted further state action; (2) if the stated federal inter-
est-such as uniformity of laws-is sufficiently dominant that Congress' "intent to
supersede state law ... may be found" from a pervasive regulatory scheme; or (3)
if state law conflicts with federal law. Id.
In the case of RU 486, the safety and efficacy of the drug will be evaluated
by the FDA before it is available for distribution in this country. Although the
Food, Drug and Cosmetic Act does not explicitly preempt state regulation of drug
distribution, there is a strong federal interest in establishing national uniform
standards concerning consumers' access to drugs. The FDA uses the drug approval
process, labelling requirements and by-prescription-only status to limit consumers'
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tions on access to RU 486 would violate their privacy interests
and fundamental right to birth control and, in the case of wom-
en seeking to take RU 486 three or four weeks after concep-
tion, such restrictions would violate women's right to choose
abortion. Third, women would argue that restrictions that limit
the use of RU 486 within two weeks of fertilization violate the
Equal Protection Clause of the Fourteenth Amendment. The
following exploration focuses on the last two of these argu-
ments, emphasizes the development of privacy rights and sug-
gests that the Court-if it seeks to uphold states' attempts to
regulate RU 486's distribution-will find itself constrained by
its privacy rights decisions. Indeed, the emergence of RU 486
as a reproductive technology may result in a future Supreme
Court decision reestablishing a woman's fundamental consti-
tutional right to choose abortion without state-imposed re-
striction in the first few weeks after fertilization and implanta-
tion.
As a result of thirty years of court decisions involving
privacy rights, few state restrictions on the use of contracep-
tives are constitutionally permitted, but the right to abortion
may be regulated rather freely as long as regulations do not
overburden the exercise of that right. The Court's most recent
decision on abortion regulations firmly reiterates and, at least
rhetorically, further enhances the constitutionally privileged
purchases of potentially harmful medicines. This regulatory scheme is detailed and
rigorous. As such, the federal regulation of drugs by the FDA represents a com-
prehensive process ensuring drugs' safety and efficacy. The national regulatory
scheme also provides pharmaceutical companies with a national market free of
piece-meal, specialized state regulations which would inhibit interstate commerce.
Since the FDA's complex scheme serves two substantial federal interests,
namely guaranteeing that only safe and effective drugs will be sold to American
consumers and establishing a national marketplace for pharmaceuticals, Congres-
sional intent to preempt further regulation reasonably may be inferred. States
seeking to limit distribution of RU 486 would have to rest their authority to do so
on some equally substantial state interest, and any regulatory proposal could not
directly conflict with existing federal law. States probably would assert interests in
maternal health, the safety of the drug and fetal life. Since Congress explicitly
charged the FDA with regulating drugs' efficacy and safety, the federal scheme
should effectuate the first two asserted state interests. As for the state interest in
fetal life, states would have to demonstrate that their interest in fetal life begin-
ning at the moment of conception, standing alone, is so significant that the pre-
emption doctrine should not apply to state regulation of RU 486. Even under
Casey, it is unlikely that the Court would characterize a state interest in a fertil-
ized egg at the moment of conception as substantial.
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status of the right to contraceptives.21 Since RU 486 has a
dual nature as both a contraceptive and an abortifacient, at-
tempts by states to regulate the drug will be complicated by
the Court's relatively recent emphasis of the distinction be-
tween contraception and abortion, and its reliance on that
distinction to legitimize greater state regulation and restriction
of abortion. Presumably, if the right to contraception-as dis-
tinguished from the right to abortion-had not been empha-
sized as a result of the change in the abortion right's constitu-
tional status, the right to contraception would be less en-
trenched in the Court's privacy jurisprudence. Furthermore, if
the Court had not distinguished the right to contraception,
state regulation of RU 486 perhaps would be easier to justify
constitutionally. But particularly after Casey, the Court would
have a difficult time upholding distribution restrictions on RU
486 without providing a sharply different interpretation of
privacy rights. Ultimately, RU 486 may prove to be a scientific
development that forces the court to directly confront whether
a woman has a fundamental constitutional right, as she did
under Roe v. Wade, to choose abortion in the first few of preg-
nancy-a choice that is possible using RU 486 but not the
surgical abortion technique-rather than merely a right that
cannot be unduly burdened.
The distinction between contraception and abortion is a
relatively recent one in constitutional jurisprudence. In the
late 1960s and 1970s, the Court did not differentiate the con-
stitutional rights at issue; rather, the Court recognized that
the right to privacy translated into a fundamental right to use
birth control and to have an abortion.
1. Birth Control Cases
The landmark opinion in Griswold v. Connecticut was the
first to recognize that the constitutional right to privacy, origi-
nating in the First, Third, Fourth, Fifth, Ninth and Fourteenth
Amendments, included a derivative right to use contracep-
tives.21' The Griswold Court considered whether the execu-
tive director and the medical director of a health clinic could be
210 Planned Parenthood v. Casey, 112 S. Ct. 2791, 2807 (1992).
21 381 U.S. 479, 485-86 (1965).
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prosecuted under a criminal state statute for giving "informa-
tion, instruction, and medical advice to married persons" re-
garding contraceptives and for prescribing contraceptive devic-
es.212 The Court's conclusion that the statute was unconstitu-
tional set the stage for the next constitutional challenge to
state limits on access to birth control.
Although Griswold involved the rights of married persons,
seven years later the Supreme Court extended constitutional
protection to single persons seeking access to contraceptives.
The Court's decision in Eisenstadt v. Baird concluded that a
state statute criminalizing the distribution of contraceptives to
unmarried persons, but permitting distribution to married
persons, violated the Equal Protection Clause of the Four-
teenth Amendment.213 Unequivocally stating that no mean-
ingful distinction could be drawn between the privacy interests
of individuals in marital relationships and single individuals,
the Court stated that both groups must have equal access to
contraceptives. In one of the most quoted sentences in subse-
quent privacy jurisprudence, the Court articulated its ratio-
nale: "If the right to privacy means anything, it is the right of
the individual, married or single, to be free from unwarranted
governmental intrusion into matters so fundamentally affect-
ing a person as the decision whether to bear or beget a
child."214 Thus, after Eisenstadt, an individual's right of ac-
cess to contraceptives was constitutionally guaranteed. There-
fore, an outright ban on a particular contraceptive technology,
such as RU 486, would appear to be constitutionally invalid
under Eisenstadt.1 5
212 Id. at 480.
213 405 U.S. 438, 443 (1972) (lecturer on contraception gave contraceptive foam
to an unmarried female student in violation of a state law prohibiting contracep-
tive distribution to unmarried persons for contraceptive purposes).
214 Id. at 453.
2' Both Griswold and Eisenstadt, as well as other privacy cases such as Roe v.
Wade, were cited with approval in Planned Parenthood v. Casey. See infra notes
219-23 and accompanying text.
In addition to recognizing a constitutional right of access to contraceptives for
unmarried persons, Eisenstadt presents a model for evaluating the constitutional
status of restrictions on access to contraceptives. Since some states will seek to
regulate the distribution of RU 486 as a birth control method, Justice White's
concurrence, joined by Justice Blackmun, indicates that a state would have to
demonstrate a compelling state interest for the Court to affirm the constitutional
validity of such restrictions. Id. at 463-64. And this strict scrutiny standard re-
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A number of years following Eisenstadt, the Court again
considered the right of access to birth control in Carey v. Popu-
lation Services International, concluding that the right to birth
control is fundamental, and that any state regulation involving
contraceptives must be based on a compelling state interest
mains the appropriate standard of review for regulations of contraceptives even
after Casey. Justice White argued that if a state asserts a public health interest
in regulating a contraceptive that may pose a health risk, "we may not accept on
faith the State's classification of a particular contraceptive as dangerous to health.
Due regard for protecting constitutional rights requires that the record contain
evidence that a restriction on distribution of vaginal foam [and other contracep-
tives] is essential to achieve the statutory purpose." Id. at 464. Thus, a state stat-
ute criminalizing the distribution of contraceptives that are to be sold only pursu-
ant to a prescription would presumably be constitutional under Eisenstadt. Since
the FDA restricts access to other chemical contraceptives, such as the birth control
pill, Depo-Privera and Norplant, to sale by prescription only, it is likely that RU
486 would be regulated similarly. Then states could constitutionally prohibit over-
the-counter sales of RU 486 by arguing the states' interests in public health.
More constitutionally suspect than statutes restricting RU 486 to sale-by-pre-
scription-only status would be any additional state regulations peculiar to the
distribution of RU 486 and not other chemical contraceptives. Since the Eisenstadt
Court characterized a prescription requirement for access to a birth control method
as "a substantial burden" to place on the exercise of a constitutional right, any
additional restrictions would augment the substantial burden felt by a woman
seeking to use a chemical contraceptive like RU 486. Even if the prescription
requirement is justified by a strong state interest in public health, under
Eisenstadt a state would have to make a strong evidentiary showing that further
procedural restrictions-beyond the prescription requirement-would be warranted
by a state interest in health. And the nature of these state-imposed restrictions
also would be at issue: it appears unlikely that the Court would even entertain a
state's assertion of an interest not related to the health of the contraceptive user.
For example, in Eisenstadt, the Court dismissed Massachusetts' asserted interest
in deterring premarital sexual intercourse, ridiculing it as "prescrib[ing] pregnancy
as punishment for fornication." Id. at 448.
Although the Eisenstadt Court glossed over the question of whether a state
could restrict access to contraceptives to further some other state interest, resting
its decision on the disparate treatment of married and single persons, in the case
of RU 486 the state's interest in health would be protected by the sale-by-prescrip-
tion-only requirement. Id. at 453. Any health risks that a woman would encounter
by using RU 486 would be managed through the medical protocol prescribed by
the dispenser of the drug. Other proposed state regulations that states might want
to adopt modeled after restrictions on access to abortion, such as waiting periods,
state-mandated counseling to encourage a woman to carry a pregnancy to term
and parental consent provisions, would have to be justified by a state's interest
not in the woman's health, but rather in a potential pregnancy that might occur if
a woman did not use the drug as a contraceptive. After Eisenstadt, it seems un-
likely that a state could show a sufficiently compelling reason to justify additional
restrictions on access to RU 486 as a contraceptive. The Court probably would in-
validate this type of regulation as interfering with the exercise of the fundamental
constitutional right to contraceptives.
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and must be narrowly tailored to meet the asserted inter-
est."6 The Carey opinion demonstrates how the Court at that
time connected the right to birth control and the right to abor-
tion: "[riestrictions on the distribution of contraceptives clearly
burden the freedom to make such decisions," and limiting their
distribution through licensed pharmacists "clearly imposes a
significant burden on the right of the individuals to use con-
traceptives." The Court thus drew an analogy to access to abor-
tion; restrictions on access to contraceptives and abortion ser-
vices must survive strict scrutiny, and the state must be able
to demonstrate a compelling interest to justify any regula-
tion.21
7
Although subsequent cases have lessened the stringency of
the standard of review of restrictions concerning abortion,
Carey reflects the development of privacy jurisprudence and
the theoretical interconnectedness of the constitutional right to
contraceptives and abortion services. At the philosophical cen-
ter of each major decision in birth control cases is the notion of
independent individual judgment and private decisionmaking.
During this period before the Court began to uphold state
restrictions on abortion services, the Court conceived of the
privacy right as applying to both decisions about conception
and abortion. Carey expresses this underlying principle by
noting that the right to contraceptives should be seen not as
constitutionally distinct but as part of the "constitutionally
protected right of decision in matters of childbearing that is
the underlying foundation of the holdings in Griswold,
Eisenstadt v. Baird and Roe v. Wade."218
2. Birth Control Versus Abortion
The conceptual synthesis that marked the Court's deci-
sions regarding the right to birth control and the right to abor-
tion ended definitively in 1992 with the Court's opinion in
216 431 U.S. 678 (1977) (states may not ban mail-order company from distribut-
ing contraceptives, must demonstrate a compelling state interest when seeking to
regulate distribution of contraceptives and may not constitutionally proscribe ad-
vertising of contraceptives).
217 Id. at 687-89.
218 Id. at 688-89.
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Planned Parenthood v. Casey.219 This case is notable both for
the philosophical shift it embodies and for what clues it holds
regarding future privacy jurisprudential development and
what, if any, future constitutional protection will be accorded
to RU 486.
In Casey, the Court declared the right to contraceptives as
even more explicitly sacrosanct than in prior opinions, while
fundamentally undercutting the right to abortion. The opinion
supports, at length and with eloquence, the existence of a fun-
damental right to birth control, notes that precedent connects
the premises behind the birth control right to the constitution-
al underpinnings of the abortion right and, then, in a theoreti-
cal shift from the earlier birth control cases, explains that the
constitution simply does not protect the act of abortion in the
same way that it does birth control.
The Casey decision substantially eases the standard for
review of statutory restrictions on abortion, holding that only
those restrictions that imposed an "undue burden" on the exer-
cise of the abortion right would be unconstitutional.2 As the
Casey Court changed the standard of review for statutory re-
strictions on the right to abortion, radically increasing the
number of restrictions that are constitutionally permissible,
the Court distinguished the right to abortion from the right to
contraceptives.22' Nevertheless, in the case of the right to
birth control, the Court adhered to the premises underlying
constitutional protection of this right, reiterating again the
guarantee of Griswold, Eisenstadt and Carey:
there is a realm of personal liberty which the government may not
enter.... It is settled now, as it was when the Court heard argu-
ments in Roe v. Wade, that the Constitution places limits on a
State's right to interfere with a person's most basic decisions about
family and parenthood."
The Court even went so far as to state frankly that "[in some
critical respects the abortion decision is of the same character
as the decision to use contraception to which [Griswold,
Eisenstadt and Carey] afford constitutional protection. We have
219 112 S. Ct. 2791 (1992).
220 Id. at 2821.
221 "Abortion is a unique act." Id. at 2807.
22 Id. at 2805 (citing Carey, Eisenstadt and Griswold among others).
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no doubt as to the correctness of those decisions."22 Thus,
Casey sets forth two profoundly different levels of constitution-
al protection accorded to two related activities-choosing a
contraceptive and choosing an abortion which are closely con-
nected in their aim-the avoidance of pregnancy and child-
birth, but not traditionally in time.
Hence, as a result of Casey, the Court has two distinct
standards: the Court will strictly scrutinize state restrictions
on contraceptives but will uphold regulations on abortions as
long as they are rationally related to a state interest and do
not impose a substantial burden on the right to choose. After
Casey, stare decisis would make it difficult to revisit the consti-
tutionality of statutory restrictions on contraception. Yet some
states will undoubtedly seek to impose such restrictions when
RU 486 becomes available as a contraceptive. At that time, if
the Court attempts to reason that state regulation of RU .486
either as a contraceptive or early-stage abortifacient is consti-
tutional, it will find itself confronted by its lyrical pronounce-
ments about the special constitutional protection afforded birth
control use.
3. Constitutional Regulation of RU 486?
The Court's analytical distinction between contraception
and abortion, which provides a constitutional basis for state re-
strictions on abortion, cannot survive the development of RU
486 as the following set of related hypotheticals will demon-
strate. In fact, the Court's discussion of this distinction in
Casey may make constitutionally valid statutory regulation of
RU 486224 more unlikely unless the Court is willing to nar-
2 Id. at 2807.
" The hypotheticals assume that any state regulation is more detailed and
burdensome than a prescription requirement. Under Eisenstadt, see supra note 215,
requiring a prescription to obtain potentially dangerous contraceptive material may
place a substantial burden upon the right recognized in Griswold, but that burden
is justified by a strong state interest and does not, as did the statute at issue in
Griswold, sweep unnecessarily broadly or seek 'to achieve its goals by means hav-
ing a maximum destructive impact upon' a protected relationship. Griswold v.
Connecticut, 381 U.S. 479, 485 (1965). Federal determination of which drugs will
be placed on the by-prescription-only schedule is less troubling because the federal
interests in safety and efficacy are indisputable. Additional distribution require-
ments to be imposed on drugs by states, however, do raise the question of what
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row sharply its interpretation of Casey and characterize the
right to birth control as less than fundamental.
Consider the following hypothetical:
Woman A seeks to use RU 486 as a birth control method at a fairly
low daily dosage. She is not pregnant. Her state of residence passes
a statute sharply restricting access to the drug, arguing that al-
though it may be used as a birth control pill, RU 486 may also be
used as an abortifacient. The state asserts, therefore, that the stat-
ute is constitutional. The woman brings a suit arguing that her
constitutional right to choose a birth control method is violated by
the restrictive statute and that she has chosen to use RU 486 for
health reasons because it is safer than standard birth control pills
and IUDs.
Since RU 486 is the only drug that appears to function as
both a method of birth control and an abortifacient after im-
plantation,225 it is unclear how the Court would interpret
state statutes that might seek to limit access to the drug once
it was approved for use. Nevertheless, because the drug would
function like birth control pills and IUDs, preventing implan-
tation of a fertilized egg in the wall of the uterus, a woman
presumably could assert successfully her fundamental constitu-
tional right to choose a form of birth control. She would argue
that the state can not demonstrate a sufficiently compelling
state interest that trumps her privacy interest. This is espe-
cially true if RU 486 presents a lesser health risk than other
non-barrier birth control methods. Woman A could cite Casey
and Griswold's progeny in support of her position, characteriz-
state interest is being promoted.
The morning after pill, a form of birth control pill, only works up to 72
hours after fertilization; the IUD will only impede implantation and will not typi-
cally cause a fetus to be expelled. See also Martha A. Field, Killing "The Handi-
capped"--Before and After Birth, 16 HARV. WOMEN'S L.J. 79 (1993). She describes
implantation:
The embryo up to this point is sometimes described as a "pre-embryo,"
more similar to organs or tissue than to anything that is alive. The pre-
embryo has much less chance for survival than an implanted embryo.
Before implantation, the fertilized ovum has a few undifferentiated cells
but no organ structure and no spinal column .... Twinning also can
take place prior to implantation but not after. If state legislatures were
given a free hand to cut back on abortion a state might try to use this
time as the cut-off for abortion. The embryo would be considered life but
the pre-embryo would not be.
Id. at nn.214-16 and accompanying text. Implantation is complete fourteen days
after fertilization.
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ing as fundamental her right of access to RU 486 as a contra-
ceptive. Moreover, under these cases, a state would have to
show a compelling state interest in a potentially fertilized egg
before a statute restricting a woman's use of RU 486 could be
upheld. But under the strict scrutiny standard, it is unlikely
that a state could successfully make this showing.
In addition to her privacy rights argument, Woman A
would also assert that state restrictions violate her right to
equal protection under the Fourteenth Amendment. As the
Supreme Court stated in San Antonio v. Rodriguez, where the
exercise of a fundamental right is at issue, a state must treat
similarly situated persons equally." 6 A state may not inter-
fere with the exercise of the right without demonstrating a
compelling interest for doing so. 7 Under Rodriguez, a court
would apply strict scrutiny when evaluating a state's regula-
tion of RU 486.228 Woman A would claim that her fundamen-
tal right is abridged by the state's regulation and that the
state has not asserted a compelling interest to support the
state statute. She would note that she is identically situated to
a woman using an IUD or birth control pills. A court probably
would be persuaded by this argument and invalidate the regu-
lation on equal protection grounds as well.
Contrast the following hypothetical to the one above.
Woman B, who does not use RU 486 as a birth control method, visits
her doctor believing that an egg was fertilized. Because she is within
fourteen days of fertilization, however, implantation has not taken
place. She asks her physician for a prescription for a higher single
dose of RU 486 and for a prostaglandin. Her state has enacted a
statute which permits wide access to the lower dosage of RU 486
associated with its use as a birth control method, but which imposes
restrictions on access to the higher single dosage of RU 486. The
state characterizes RU 486 as an abortifacient and imposes restric-
tions that are similar to restrictions on abortion services. The re-
strictions include parental consent for minors, a procedure whereby
a woman must receive specific counseling by a doctor emphasizing
the value of childbirth and risks associated with abortion and a 24-
'6 411 U.S. 1 (1973) (since education is not a fundamental right and wealth is
not a suspect classification, state education financing scheme that relies on local
districts to supplement state aid with local property taxes does not violate the
equal protection rights of school children from poorer school districts).




hour waiting period before receiving the drug."9 The state would
argue that, under these circumstances, the woman must demon-
strate that these restrictions are constitutionally invalid for they do
not impose an undue burden on Woman B's ability to obtain an
abortion.
Since RU 486 functions medically like the birth control pill
or IUD, Woman B is similarly situated to Woman A and would
assert similar privacy and equal protection arguments."'
Even if the state were to regulate access to RU 486 based on
Woman B's intent or the dosage of RU 486 she seeks, those
regulations similarly would fail.
Should the state be able to restrict Woman B's access to
RU 486 if it knows that the drug is being sought deliberately
to avoid implantation and pregnancy, even though the drug
functions in the same way for Woman A? What state interest
is at stake and how should that interest be compared with
Woman B's privacy interest? The state could not reasonably
assert a compelling interest in a fertilized egg, even under
Casey. The only interest the state could assert would be
grounded in its expectation that, if left alone, the fertilized egg
would implant.23' Since under these circumstances the drug
functions like other contraceptives, the question of Woman B's
intent presumably would not control which standard of review
would apply.2
One indicia of intent would be RU 486 dosage level. Since
the state could not adequately demonstrate a compelling inter-
est in a fertilized egg, regulations based on dosage, therefore,
22 Planned Parenthood v. Casey, 112 S. Ct. 2791, 2822-33 (1992).
o She carries a fertilized egg but implantation has not taken place. The dose
of RU 486, acting like the pill or an UD, will cause her to expel the egg.
" But that has never been sufficient to allow the state's interest to trump the
woman's privacy interest. Indeed, under Casey, not only does a woman have a con-
stitutional right to avoid implantation through the use of contraceptives, but she
also has a right to abort an implanted fetus up until the ppoint of viability.
Thus, by logic, the state could not have a greater right in a fertilized, but not-yet-
implanted, egg.
' Clearly since it is difficult for a woman to know precisely when she ovulates
and even more difficult to approximate the time fertilization or implantation oc-
curs, any attempt by a state to regulate the administration of RU 486 immediate-
ly after fertilization seems impractical at best. If a state wanted to regulate access
to RU 486 when a woman's use of the drug could be characterized as causing an
abortion, the question becomes how to make this determination. Is it at three
weeks post-fertilization? At four weeks?
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also would be constitutionally invalid. Even though states
might characterize RU 486 as an abortifacient, Casey-like
restrictions imposed on Woman A's use of RU 486 as a birth
control method or on Woman B's use of RU 486 to avoid im-
plantation would not survive the Court's scrutiny under either
a privacy or equal protection rights rationale.
Finally, consider a third hypothetical.
Woman C has been using a barrier contraceptive method, misses her
period and suspects she is pregnant. She believes she is three weeks
pregnant and if she cannot gain access to RU 486, she will have to
wait an additional three weeks for a surgical abortion. Even though
her state of residence wants to restrict sharply access to abortifa-
cient drugs, it has been frustrated by the Court's decisions in
hypotheticals one and two. The state argues that this is a case
where there is no ambiguity concerning the use of RU 486 as a birth
control method. Woman C suspects that implantation has occurred
and she is certain that she wants to terminate the pregnancy. She
would argue that at this stage in pregnancy, her interest in her
right to choose abortion trumps any state interest in fetal life.
Woman C's argument presents a novel question for the Court's
consideration.
In light of these hypotheticals-and to answer the consti-
tutional question posed by Woman C's dilemma-one must
consider how the approval of RU 486 will influence the devel-
opment of constitutional jurisprudence concerning birth control
and abortion. The development of RU 486 may require the
Court to hold once again, as it had in Roe v. Wade, that women
have a fundamental constitutional right to choose abortion in
the first six weeks after fertilization. The Court has never tried
to balance individual liberty and privacy interests against
state interests in the first six weeks of pregnancy. Since surgi-
cal abortions generally are performed after six weeks of preg-
nancy, modem courts never have been faced with this
dilemma. 3 Nor have the courts tried to regulate a drug that
' Surgical aspiration abortions generally are performed once a pelvic exam
confirms pregnancy, five or six weeks after fertilization. If a surgical abortion is
performed prior to six weeks, there is a possibility that the abortion will not be
successful. See THE BOSTON WOMEN'S HEALTH COLLECTIVE, THE NEW OUR BODIES
OURSELVES 294-96 (1984).
Note that at common law, abortion was permissible until the time of "quick-
ening," when a woman would feel fetal movements in her uterus. Casey, 112 S.
Ct. at 2859 (Rehnquist, C.J., dissenting in part and concurring in part).
1994l
BROOKLYN LAW REVIEW
confounds easy categorization as a birth control method or an
abortifacient. Therefore, most of the constitutional debate
about abortion has focused on questions of viability and a tri-
mester framework, based on three-month intervals, to evaluate
and determine the rights of the woman vis-A-vis the state.'
What the Supreme Court has not considered is the vague-
ness-historically, philosophically, physically and morally-of
the first days, first weeks and first month during which an egg
is fertilized and implanted. And yet the development of RU 486
and Woman C's arguments challenge the Court to shift radical-
ly its focus to this ambiguous time in pregnancy.
The hypotheticals above, especially Woman C's unique
situation, suggest that because the Court has drawn a strict
line between birth control and abortions and, correspondingly,
has characterized a woman's constitutional privacy interests in
contraception and abortion very differently, the Court is at a
jurisprudential crossroads. The Supreme Court will have to
consider whether its separate analysis and differentiation of
the constitutional rights associated with birth control and
abortion remain meaningful if the applicable constitutional
standard depends not on viability but on fertilization, implan-
tation and the fourteen days thereafter.23 Since RU 486 may
"z4 Casey rejects the trimester framework articulated by Roe in favor of drawing
a line at viability, at which point states may limit a woman's ability to choose
abortion significantly. Id. at 2821. Other restrictions such as mandated counseling
sessions, counseling waiting periods and parental consent requirements are permis-
sible even before viability. Id. at 2822-33.
' RU 486 provides an opportunity to reconstruct the constitutional debate
itself and locate a woman's abortion decision at a time when the fetus is irrefut-
ably dependant on the woman's life. At three weeks after fertilization, for example,
viability is not in question and even birth is less of a certainty. Pro-life advocates
could not suggest that the fetus could live outside of the woman, even with tech-
nological assistance. Thus, with the development of RU 486, pro-choice advocates
could challenge the Court's historical focus on viability as misplaced.
The Court has traditionally considered the state interest in a fetus primarily
by identifying when the fetus could live outside the woman. As scientific technolo-
gy has improved, the point of viability has moved closer to conception. The court
has emphasized that Roe v. Wade's trimester structure was flawed precisely for
this reason. Therefore, the significance of the state interest has been conceptual-
ized and evaluated by focusing on viability.
Proponents of women's right to choose abortion would argue that, by focusing
on viability, the Court has emphasized the likelihood that the fetus will be born,
thus maximizing the state interest. Pro-choice advocates could respond that via-
bility, as an analytical framework for understanding women's constitutional inter-
ests, inappropriately minimizes these interests and could use RU 486 to refocus
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be used as a birth control method, any restrictions on its use
must be tested against a woman's fundamental right to use
birth control, particularly because it is intellectually disingenu-
ous to distinguish between the use of RU 486 as a birth control
method or "abortifacient" prohibiting implantation."6 And as
the hypotheticals demonstrated, it would be extremely difficult
to restrict the use of RU 486 as an abortifacient a few weeks
after implantation without engaging in the relatively inaccu-
rate and difficult job of trying to categorize users of the drug
based on their menstrual cycles to determine which group
would be subject to further regulation. Therefore, state stat-
utes imposing Casey-like restrictions on RU 486 either as a
contraceptive or abortifacient would be unconstitutional.
In summary, RU 486 may provide the Court with a means
to unify its constitutional privacy jurisprudence by presenting
a factual circumstance that confounds the Court's theoretical
distinction between birth control and abortion rights. With the
development of RU 486, the Court may conclude that Casey's
undue burden standard is an inappropriate test for balancing a
woman's constitutional privacy interest against a state's inter-
est in a fetus just a few weeks after fertilization. Instead, the
Court may eventually hold that women have a fundamental
the abortion debate.
" A constitutional problem also arises in the context of drafting a statute
restricting access to the drug. How can the statute be worded to impose re-
strictions on women like Woman C in the early weeks after implantation but
leave Woman B's access unrestricted in light of her "fundamental constitutional
right" to birth control? Would this law then require Woman B-whose fertilized
egg has not implanted-to prove when her last period occurred in order to show
that she "stands in the shoes" of Woman A, who uses RU 486 as a birth control
method, so that Woman B can obtain RU 486 without restrictions? This kind of
requirement is unworkable. Women's menstrual cycles vary; even a woman who is
accustomed to an average cycle of twenty-eight days may ovulate late one month.
That woman erroneously would think that she was like Woman C when, in actual-
ity, she would be like Woman B. And many women do not have cycles that are
predictable enough to be able to tell definitively when they had ovulated, when
the egg would have been fertilized and when the egg would have been implanted.
The practical problems of enforcing such a rule seem too great. Then could the
statute impose restrictions on access to certain dosages? Such a statute would fail
also because of the problems articulated in hypothetical two. Thus, the third hypo-
thetical suggests that the state would have a very difficult time writing a constitu-
tionally valid statute restricting women's access to RU 486. This would be true
even though Woman C is more like the contemporary woman seeking a surgical
abortion, where the Court has recognized the state's interest in imposing certain
restrictions even during the first trimester. Casey, 112 S. Ct. at 2822-33.
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right to RU 486 as an abortifacient.
This exploration of what the development of RU 486
means for the future of constitutional privacy doctrine demon-
strates that the public has a clear stake in the governmental
regulation of RU 486. The uniqueness of the drug's properties
has encouraged people to speak out about the drug and sug-
gests that creating an opportunity for public comment about
the drug's availability in the United States would have served
the public interest. Since RU 486 has promise as a new form of
birth control and abortion, the legal significance of the drug's
character is of particular interest to women as a class.
CONCLUSION
Benten v. Kessler offered the Supreme Court an opportuni-
ty to comment on three substantive issues, namely, whether
the import ban was a legislative rule under the APA, whether
judicial review of the FDA's import ban was appropriate and
whether the agency's action was arbitrary and capricious. The
Supreme Court's virtual silence in response suggests that,
particularly on controversial topics, the High Court prefers to
allow an agency great latitude in its enforcement decisions,
even when an agency appears to have acted improperly.
Yet the Supreme Court's reticence to review the FDA's
decision to guarantee sufficient public involvement in agency
rulemaking is troubling. The FDA's actions with regard to RU
486 were hasty and violated both the agency's internal regula-
tions and the requirements of the APA. The import ban effec-
tively shut down a channel for public debate about the drug by
eliminating an opportunity for the public-and, particularly,
women-to make their views known through the APA's notice
and comment procedure. Furthermore, the FDA's actions were
not founded on a thoughtful examination of the relevant health
and safety data on RU 486. Even so, only the district court in
Benten considered whether judicial review was appropriate and
whether the ban should be voided as arbitrary and capricious.
The importance of participatory administrative rulemaking
cannot be overstated in light of the broad discretion exercised
by administrative agencies. In the interest of ensuring that the
public may "weigh in" on issues it believes are important,
courts should require that agencies scrupulously follow the
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APA rulemaking model. This is especially true where, as Part
III of this Note has demonstrated, highly charged issues of
abortion and birth control restrictions may affect the substan-
tive privacy rights of all American women.
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